UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
☑ Filed by the Registrant | ☐ Filed by a Party other than the Registrant |
Check the appropriate box:
| ||
☐
|
Preliminary Proxy Statement
| |
☐
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
| |
☑
|
Definitive Proxy Statement
| |
☐
|
Definitive Additional Materials
| |
☐
|
Soliciting Material Pursuant to § 240.14a-12
|
AMN HEALTHCARE SERVICES, INC.
(Name of Registrant as Specified in its Charter)
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)
Payment of Filing Fee (Check the appropriate box):
| ||
☑
|
No fee required.
| |
☐ |
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
| |
(1) Title of each class of securities to which transaction applies:
| ||
(2) Aggregate number of securities to which transaction applies:
| ||
(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
| ||
(4) Proposed maximum aggregate value of transaction:
| ||
(5) Total fee paid:
| ||
☐
|
Fee paid previously with preliminary materials.
| |
☐ |
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
| |
(1) Amount Previously Paid:
| ||
(2) Form, Schedule or Registration Statement No.:
| ||
(3) Filing Party:
| ||
(4) Date Filed:
|
AMN HEALTHCARE 2018 notice of annual meeting & proxy statement The Innovator in Healthcare Workforce solutions and staffing services
March 8, 2018
To Our Fellow Shareholders:
We are pleased to invite you to attend our 2018 Annual Meeting of Shareholders (the Annual Meeting) of AMN Healthcare Services, Inc. at our corporate office located at 8840 Cypress Waters Boulevard, Suite 300, Dallas, Texas 75019 on Wednesday, April 18, 2018, at 8:30 a.m. Central Time. The accompanying formal notice of the Annual Meeting and proxy statement set forth the details regarding admission to the Annual Meeting and the business to be conducted.
Our annual meetings provide us with yet another opportunity to meet with our shareholders and discuss our strategy, corporate governance, and other related matters. We place high importance on maintaining an ongoing dialogue with our shareholders, and do not limit our conversations to the Annual Meeting. In addition to the Annual Meeting and our discussions at investor conferences, we also engage our shareholders through a formal outreach program in which we invite our shareholders to discuss our culture, corporate governance, executive compensation, corporate social responsibility program, and any other matters that may be of interest to them. We found these interactions to be very beneficial and discuss this in more detail in our proxy statement. We truly value communicating with and receiving feedback from our shareholders and look forward to continuing these conversations in 2018.
In connection with the Annual Meeting, we encourage you to review our Annual Report for the fiscal year ended December 31, 2017. The formal notice of the Annual Meeting has been sent to you, along with the proxy statement and proxy card, unless you have elected to receive materials electronically. It is important that your shares be represented and voted, regardless of the size of your holdings. Accordingly, whether or not you plan to attend the Annual Meeting, we encourage you to access the proxy materials and vote online in accordance with the Notice and Access letter you will receive so that your shares will be represented at the Annual Meeting. In the alternative, you may also complete, sign, date, and return the proxy card if you wish to receive a full set of proxy materials by mail. Finally, please keep in mind, the proxy is revocable at any time before it is voted and will not affect your right to vote in person if you decide to attend the Annual Meeting.
On behalf of the Board of Directors and the Company, we want to thank you for your ongoing support of and continued interest in AMN Healthcare, and we hope to see you at the Annual Meeting.
Sincerely,
Susan R. Salka President & Chief Executive Officer |
Douglas D. Wheat Chairman of the Board |
Page | ||||
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS | ||||
|
|
1 |
| |
|
|
2 |
| |
|
|
6 |
| |
|
|
15 |
| |
|
|
15 |
| |
16 | ||||
16 | ||||
17 | ||||
18 | ||||
20 | ||||
21 | ||||
Our Boards Policy on Conflicts of Interest and Related Party Transactions |
21 | |||
Board Meetings and Annual Meeting Attendance by Board Members |
22 | |||
22 | ||||
25 | ||||
25 | ||||
DIRECTOR COMPENSATION AND OWNERSHIP GUIDELINES | 26 | |||
|
|
26 |
| |
26 | ||||
27 | ||||
27 | ||||
COMPENSATION DISCUSSION AND ANALYSIS | 28 | |||
|
28 | |||
28 | ||||
32 | ||||
33 | ||||
35 | ||||
37 | ||||
39 | ||||
Equity Ownership Requirements, Clawback and No Pledging Policies |
46 | |||
46 | ||||
47 | ||||
COMPENSATION COMMITTEE REPORT | 49 | |||
|
50 | |||
|
|
|||
|
50 | |||
51 | ||||
53 | ||||
54 | ||||
56 | ||||
57 | ||||
Termination of Employment and Change in Control Arrangements |
58 | |||
60 | ||||
TABLE OF CONTENTS
12400 High Bluff Drive, Suite 100
San Diego, CA 92130
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS
Meeting Date
|
Wednesday, April 18, 2018
| |
Meeting Time
|
8.30 a.m. (Central Time)
| |
Meeting Location
|
8840 Cypress Waters Boulevard, Suite 300 Dallas, Texas 75019
| |
Record Date
|
Wednesday, February 21, 2018
|
The Annual Meeting of Shareholders (the Annual Meeting) of AMN Healthcare Services, Inc. will be held at our office located at 8840 Cypress Waters Boulevard, Suite 300, Dallas, Texas 75019 on Wednesday, April 18, 2018, at 8:30 a.m. Central Time, or at any subsequent time that may be necessary by any adjournment or postponement of the Annual Meeting. The purpose of the meeting is to:
(1) | elect eight directors nominated by our Board of Directors to hold office until our next annual meeting or until their successors are duly elected and qualified, |
(2) | approve, by non-binding advisory vote, the compensation of our named executive officers, |
(3) | ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018, and |
(4) | transact such other business, including consideration of a shareholder proposal if properly presented, as may properly come before the Annual Meeting or any adjournment or postponement of the Annual Meeting. |
The Board of Directors has fixed the close of business on February 21, 2018 as the record date for determining the shareholders of the Company entitled to notice of and to vote at the Annual Meeting or any adjournment thereof. Representation of at least a majority of the voting power represented by all outstanding shares is required to constitute a quorum at the Annual Meeting. Accordingly, it is important that your shares be represented at the Annual Meeting.
We will be using the Securities and Exchange Commissions Notice and Access model (Notice and Access), which allows us to make proxy materials available electronically, as the primary means of furnishing proxy materials. We believe Notice and Access provides shareholders with a convenient method to access our proxy materials and vote. It also allows us to conserve natural resources in alignment with our Corporate Social Responsibility Program and reduces the costs associated with printing and distributing our proxy materials. On or about March 8, 2018, we will commence mailing by sending a Notice of Internet Availability of Proxy Materials to our shareholders containing instructions on how to access our proxy statement and 2017 Annual Report online and how to cast your vote. The Notice also contains instructions on how to receive a paper copy of the proxy statement and 2017 Annual Report.
March 8, 2018:
By Order of the Board of Directors,
Denise L. Jackson
Chief Legal Officer and Corporate Secretary
San Diego, California
YOUR VOTE IS IMPORTANT
|
WE URGE YOU TO VOTE BY TELEPHONE OR INTERNET, IF AVAILABLE TO YOU, OR IF YOU RECEIVE THESE PROXY MATERIALS BY MAIL, PLEASE COMPLETE, SIGN, DATE, AND RETURN THE PROXY CARD PROMPTLY. PLEASE NOTE THAT IF YOUR SHARES ARE HELD BY A BANK, BROKER, OR OTHER RECORDHOLDER AND YOU WISH TO VOTE THEM AT THE MEETING, YOU MUST OBTAIN A LEGAL PROXY FROM THAT RECORDHOLDER.
|
PROXY STATEMENT SUMMARY |
To assist with your review, this summary highlights some key information that is contained throughout this proxy statement. It does not include all of the information you should consider. We recommend you read the entire proxy statement before casting your vote. Our proxy statement and other proxy materials are first being made available to our shareholders on or about March 8, 2018.
GENERAL INFORMATION (See pages 2 to 5)
Annual Meeting of Shareholders Wednesday, April 18, 2018 8:30 a.m. Central Time 8840 Cypress Waters Boulevard Dallas, Texas 75019
Record Date: February 21, 2018 Stock Symbol: AMN Exchange: NYSE Common Stock Outstanding: 47,818,707 Transfer Agent: American Stock Transfer and Trust Company, LLC State of Incorporation: Delaware Year of Incorporation: 1997 Public Company Since: 2001 Company Website: www.amnhealthcare.com
|
CORPORATE GOVERNANCE (See pages 15 to 25)
Proposal 1: The Board recommends a vote FOR each of the eight director nominees listed below:
Mark G. Foletta (Independent) R. Jeffrey Harris (Independent) Michael M.E. Johns, M.D. (Independent) Martha H. Marsh (Independent) Susan R. Salka (Management) Andrew M. Stern (Independent) Paul E. Weaver (Independent) Douglas D. Wheat (Independent)
Director Term: One Year Director Election: Majority of votes cast 2017 Annual Meeting Attendance: 100% Board Meetings in 2017: 6 Director Attendance in 2017: 1 director absent from 1 board meeting; 2 directors absent from 1 committee meeting Standing Board Committees (Meetings in 2017): - Audit Committee: 9 - Compensation and Stock Plan Committee: 6 - Corporate Governance Committee: 5 - Executive Committee: 2
Corporate Governance Materials: http://amnhealthcare.investorroom.com/corporategovernance
OTHER ITEMS TO BE VOTED ON (See pages 62 to 66)
Proposal 2: Advisory Vote to Approve Executive Compensation
Proposal 3: Ratification of Appointment of KPMG LLP as Independent Registered Public Accounting Firm
Proposal 4: Shareholder Proposal to Lower Threshold to 10% to Call a Special Meeting of Shareholders
The Board recommends a vote FOR Proposals 2 and 3, and AGAINST Proposal 4. | |||
EXECUTIVE COMPENSATION (See pages 28 to 61)
Susan R. Salka (CEO since 2005) CEO 2017 Total Direct Compensation
Salary: $835,577 Annual Performance Bonus: $548,078 Long-Term Equity Awards: $2,299,955 All Other Compensation: $197,357 Total Compensation: $3,880,967
2017 Compensation Highlights
73% of 2017 CEO Pay = Incentive compensation (cash and equity) tied to financial performance and shareholder return
Granted performance restricted stock units based on 2019 adjusted EBITDA margin (representing 35% of total equity value granted)
Granted performance restricted stock units based on total shareholder return over a three-year period ending December 31, 2019
Pay Aligned with Performance: Yes Stock Ownership Guidelines: Yes Recoupment Policy: Yes No Pledging Policy: Yes
|
AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement 1
GENERAL INFORMATION |
When and where is the Annual Meeting?
What is Notice and Access and why did AMN Healthcare elect to use it?
Why am I receiving these proxy materials?
How can I get electronic access to the proxy materials?
2 AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement
GENERAL INFORMATION |
What is included in the proxy materials?
Who pays the cost of soliciting proxies for the Annual Meeting?
Who is entitled to vote at the Annual Meeting?
What matters will be addressed at the Annual Meeting?
What is the vote required for each proposal and what are my choices?
Proposal
|
Vote Required
|
Broker Discretionary Voting Allowed
| ||
Proposal 1: Election of eight directors
|
Majority of the votes cast
|
No
| ||
Proposal 2: Advisory vote on executive compensation
|
Majority of the shares entitled to vote and
|
No
| ||
Proposal 3: Ratification of auditors for fiscal year 2018
|
Majority of the shares entitled to vote and
|
Yes
| ||
Proposal 4: Shareholder ProposalSpecial Shareowner Meetings Improvement
|
Majority of the shares entitled to vote
and
|
No
|
AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement 3
GENERAL INFORMATION |
How does the Board recommend that I vote?
How do I vote my shares?
4 AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement
GENERAL INFORMATION |
What is the difference between shareholder of record and beneficial owner?
What will happen if I do not vote my shares?
What is the effect of a broker non-vote?
May I revoke my proxy or change my vote?
How can I find the results of the Annual Meeting?
AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement 5
PROPOSAL 1: ELECTION OF DIRECTORS |
ELECTION OF OUR DIRECTORS
Our Nominees for the Board of Directors
Eight directors are to be elected at the Annual Meeting to hold office until our next annual meeting or until their successors are duly elected and qualified, or until the director resigns, is removed or becomes disqualified. The proxy will be voted in accordance with the directions stated on the card, or, if no directions are stated, for election of each of the eight nominees listed below. Upon the recommendation of the Corporate Governance Committee, the members of the Board have nominated for election our eight current directors. The director nominees for election named below are willing to be duly elected and to serve. If any such nominee is not a candidate for election at the Annual Meeting, an event that the Board does not anticipate, the proxies will be voted for a substitute nominee(s).
The business experience, board service, qualifications and affiliations of our director nominees are set forth below.
Our Director Election Process ✓ Annual Director Elections ✓ Majority Voting in Uncontested Elections ✓ No Staggered Board ✓ Proxy Access |
WE HAVE AN INDEPENDENT BOARD OF DIRECTORS |
Meet our Audit Committee ✓ Financial Experts g 2 ✓ Financially Literate g 1 ✓ Risk Management g 1 | ||||
YES! | ✓ Separate Chair & CEO | |||||
88% | ✓ Board of Directors | |||||
100% | ✓ Compensation Committee | |||||
100% | ✓ Audit Committee | |||||
100% | ✓ Corporate Governance Committee |
The Board of Directors recommends that shareholders vote
|
6 AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement
PROPOSAL 1: ELECTION OF DIRECTORS |
Mark G. Foletta
|
|
Director Since: 2012 | Age: 57 | KEY SKILLS | |||||||||||
Audit Committee (Chair) | ✓ | Financial Expert | ✓ | Enterprise Risk | ||||||||||
Executive Vice President and Chief Executive Officer
Tocagen Inc |
✓ | Healthcare Industry | ✓ | Mergers & Acquisitions | ||||||||||
✓ | C-Suite | ✓ | Audit |
EXPERIENCE AND QUALIFICATIONS
The Board has concluded that Mr. Foletta is qualified to serve on the Board because he brings considerable audit, financial, healthcare and enterprise risk management experience as both an executive officer and director of healthcare companies. The Board has designated Mr. Foletta as a financial expert for its Audit Committee, for which he serves as Chairman. Since February 2017, Mr. Foletta has served as Executive Vice President and Chief Financial Officer of Tocagen Inc. Mr. Foletta served as the Interim Chief Financial Officer of Biocept, Inc., a publicly-traded diagnostics company, from August 2015 to July 2016 and he also served as Senior Vice President, Finance and Chief Financial Officer of Amylin Pharmaceuticals, Inc. from March 2006 until October 2012. From March 2000 to March 2006, Mr. Foletta served as Vice President, Finance and Chief Financial Officer of Amylin. Mr. Foletta received a Bachelor of Arts from the University of California, Santa Barbara. He is also a Certified Public Accountant (inactive) and a member of the Corporate Directors Forum.
BOARD EXPERIENCE
Since February 2013, Mr. Foletta has served as a director of Regulus Therapeutics Inc., and is Chairman of its Audit Committee and a member of its Nominating and Governance Committee. Since November 2014, Mr. Foletta has also served on the Board of DexCom, Inc., a publicly-traded company, where he is the Lead Director. Additionally, Mr. Foletta serves as a director of Viacyte, Inc., a privately held company. From August 2015 to July 2016, he served as a director and Chairman of the Audit Committee of Ambit Biosciences Corporation (sold in 2014), and also served as a director of Anadys Pharmaceuticals, Inc. (sold in 2011).
AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement 7
PROPOSAL 1: ELECTION OF DIRECTORS |
R. Jeffrey Harris
|
Director Since: 2005 | Age: 63 | KEY SKILLS | ||||||||||||
Corporate Governance Committee | ✓ | Compensation | ✓ | Governance | ||||||||||
Compensation and Stock Plan Committee | ✓ | Strategy | ✓ | Legal | ||||||||||
✓ Mergers and Acquisitions |
EXPERIENCE AND QUALIFICATIONS
The Board has concluded that Mr. Harris is qualified to serve on the Board because he brings considerable mergers and acquisitions experience, which is a key component of the AMNs strategy. Additionally, Mr. Harris has experience serving as a director on public company compensation and corporate governance committees, which is essential to designing and maintaining our executive compensation programs and developing our succession planning strategies. Mr. Harris served as Of Counsel at Apogent Technologies, Inc. from December 2000 through 2003, and as Vice President, General Counsel and Secretary from 1988 to 2000, when the company was named Sybron International.
BOARD EXPERIENCE
Since 2002, Mr. Harris has been involved as an investor in, and a director of, early stage companies. Mr. Harris served on the Board of Sybron Dental Specialties from April 2005 until it was acquired by Danaher Corporation in 2006. Mr. Harris served on the Board of Playtex Products, Inc. from 2001 until Energizer Holdings acquired it in October 2007. Mr. Harris was director of Prodesse, Inc., an early stage biotechnology company, from 2002 until 2009, when Gen-Probe Incorporated acquired it. Mr. Harris also served as director of Apogent Technologies, Inc. from 2000 until Fisher Scientific International, Inc. acquired it in 2004. Since 2008, he has been a director of Guy & ONeill, Inc. He currently serves on the Board of Brookfield Academy, a non-profit entity, and is Chairman of the Board and a co-founder of BrightStar Wisconsin Foundation, Inc., a non-profit economic development corporation. Additionally, Mr. Harris is a director of Somna Management, Inc. and Okanjo Partners, Inc., both early stage technology companies.
8 AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement
PROPOSAL 1: ELECTION OF DIRECTORS |
Michael M.E. Johns, M.D.
|
Director Since: 2008 | Age: 76 | KEY SKILLS | ||||||||||||
Corporate Governance Committee (Chair) | ✓
|
Healthcare Industry | ✓
|
C-Suite Leadership | ||||||||||
Compensation and Stock Plan Committee | ✓ | Operations | ✓ | Strategy | ||||||||||
Professor in the School of Medicine Emory University | ✓ Board Leadership |
EXPERIENCE AND QUALIFICATIONS
The Board has concluded that Dr. Johns is qualified to serve on the Board because he has extensive C-suite leadership and healthcare experience and is a recognized healthcare thought leader. This expertise is vital in shaping our strategy to deliver innovative and expanded service offerings as a healthcare workforce solutions company. Dr. Johns is a Professor in the School of Medicine at Emory University, where he also served as Chancellor from October 2007 through August 2012. Dr. Johns served as Interim Executive Vice President of Health Affairs for Emory University and as Interim Chairman and CEO of Emory Healthcare from September 1, 2015 through January 31, 2016. He served as the Interim Executive Vice President for Medical Affairs and Interim Chief Executive Officer of the University of Michigan Health System from June 2014 through March 2015. From 1996 to 2007, Dr. Johns served as Executive Vice President for Health Affairs and Chief Executive Officer of the Robert W. Woodruff Health Sciences Center of Emory University. From 1990 to 1996, Dr. Johns was Dean of the Johns Hopkins School of Medicine and Vice President of the Medical Faculty at Johns Hopkins University. From 1990 to 1996, Dr. Johns was Dean of the Johns Hopkins School of Medicine and Vice President of the Medical Faculty at Johns Hopkins University. Dr. Johns is a member of The National Academy of Medicine of the National Academy of Science.
BOARD EXPERIENCE
Dr. Johns serves on the Boards of Directors of Intelligent Fingerprinting, a privately held company, West Health Institute, a non-profit medical research organization, as well as several philanthropic entities. Dr. Johns served on the Board of the Genuine Parts Company from 2000 until April 2015, and at various times during his tenure, was a member of its Compensation, Governance and Nominating Committee and its Audit Committee. He also served on the Board and the Compensation Committee of Johnson & Johnson from 2005 to 2014. He is a member of the Board of Regents of the Uniformed Services University for the Health Sciences. From 1996 to 2007, Dr. Johns served as Chairman of the Board of Directors of Emory Healthcare.
AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement 9
PROPOSAL 1: ELECTION OF DIRECTORS |
Martha H. Marsh
|
Director Since: 2010 | Age: 69 | KEY SKILLS | ||||||||||||
Compensation and Stock Plan Committee (Chair) | ✓
|
Healthcare Industry | ✓
|
C-Suite Leadership | ||||||||||
Corporate Governance Committee | ✓ | Operations | ✓ | Strategy | ||||||||||
✓ Board Leadership |
EXPERIENCE AND QUALIFICATIONS
The Board has concluded that Ms. Marsh is qualified to serve on the Board because she has extensive C-suite leadership and expertise in the healthcare industry. Ms. Marshs experience and understanding of the challenges and opportunities of large healthcare facilities are immensely useful in directing our strategy to innovate and provide enhanced and expanded workforce solutions service offerings to meet our clients evolving needs. Ms. Marsh served as President and CEO of Stanford Hospital and Clinics for eight years, from April 2002 until her retirement in August 2010. Previously, Ms. Marsh served as the CEO of UC Davis Medical Center and the Chief Operating Officer of the UC Davis Health System from 1999 to 2002. Prior to that time, she served as the Senior Vice President for Professional Services and Managed Care at the University of Pennsylvania Health System, and before that as President and CEO of Matthew Thornton Health Plan in Nashua, New Hampshire.
BOARD EXPERIENCE
Ms. Marsh serves as a director of Owens & Minor, Inc. where she is the Chairperson of the Governance and Nominating Committee and also serves on its Compensation and Benefits Committee. Since October 2015, she has served as a director of Edwards Lifesciences Corporation and is a member of its Compensation and Governance Committee. She also serves on the Board and the Compensation Committee of Teichert, a privately-held company. Prior to Thoratec Corporations acquisition by St. Jude Medical in 2015, she had served on Thoratecs Board. Ms. Marsh is a past Chair of the Board of Trustees for the California Hospital Association and the California Association of Hospitals and Health Systems and a former director of Ascension Healthcare Network, a privately-held company.
10 AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement
PROPOSAL 1: ELECTION OF DIRECTORS |
Susan R. Salka
|
|
Director Since: 2003 | Age: 53 | KEY SKILLS | |||||||||||
Executive Committee |
✓ | Healthcare Industry | ✓ | C-Suite Leadership | ||||||||||
President and Chief Executive Officer AMN Healthcare Services, Inc . |
✓ | Business Development | ✓ | Operations | ||||||||||
✓ Mergers and Acquisitions |
EXPERIENCE AND QUALIFICATIONS
Ms. Salka has served as our President since May 2003 and our CEO since May 2005. The Board has concluded that Ms. Salka is qualified to serve on the Board because she has nearly three decades of healthcare services industry experience, including 27 years of experience with us in various roles, including Chief Financial Officer and Chief Operating Officer. During her service to the Company, she has helped grow our business both organically and through acquisitions into the national industry leader we are today. Prior to joining us, Ms. Salka worked at BioVest Partners, a venture capital firm, and at Hybritech, a subsidiary of Eli Lilly & Co., which Beckman Coulter later acquired.
BOARD EXPERIENCE
Ms. Salka is recognized as a leader in corporate governance and currently serves as a director of McKesson Corp., including as a member of its Corporate Governance and Audit Committees. She also serves on the Board of San Diego State University Campanile Foundation. Ms. Salka served on the Board and the Audit Committee of Beckman Coulter from 2007 until 2011, when Danaher Corporation acquired it. Additionally, she served on the Board of Playtex Products, Inc. from 2001 until Energizer Holdings acquired it in October 2007.
AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement 11
PROPOSAL 1: ELECTION OF DIRECTORS |
Andrew M. Stern
|
|
Director Since: 2001
|
Age: 68
|
KEY SKILLS
| |||||||||||
Corporate Governance Committee | ✓
|
Board Leadership |
✓
|
C-Suite Leadership | ||||||||||
Audit Committee | ✓
|
Healthcare Industry |
✓ | Strategy | ||||||||||
Senior Counsel Sunwest Communications, Inc. |
✓ Government Affairs I Public Policy |
EXPERIENCE AND QUALIFICATIONS
The Board has concluded that Mr. Stern is qualified to serve on the Board because he brings deep and long-standing healthcare industry experience as well as extensive investor communications and media expertise, which have been valuable in guiding the structure of our communications strategy with our investors, clients and other key stakeholders. Mr. Sterns lobbying and advocacy skills in the healthcare provider arena also benefit the Company and qualify him to serve on the Board. Mr. Stern is currently Senior Counsel of Sunwest Communications, Inc., a public relations firm, which he founded in 1982 and, from 1983 through the sale of Sunwest in 2017, served as Chairman of the Board and Chief Executive Officer. From 1975 to 1977, he served as Staff Assistant to President Gerald R. Ford at The White House and then served in senior corporate positions until founding Sunwest in 1982.
BOARD EXPERIENCE
Prior to serving as Senior Counsel for Sunwest Communications, Mr. Stern formerly served as its Chief Executive Officer and Chairman of the Board from 1983 to 2017. He has also served as a director of Medical City Dallas Hospital for 23 years and is the co-founder and co-chair of the Medical City Healthcare community advisory board. He is also an advisory director of the Center for Political Communication and Chairman of the Committee on Governance of the American Hospital Association. Additionally, Mr. Stern also serves as a director for Club Oaks Consulting LLC, American Hospital Association Political Action Committee, Texas Hospital Association HOSPAC and Dallas Medical Resource.
12 AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement
PROPOSAL 1: ELECTION OF DIRECTORS |
Paul E. Weaver
|
Director Since: 2006 | Age: 72 | KEY SKILLS | ||||||||||||
Audit Committee | ✓
|
C-Suite Leadership | ✓
|
Board Leadership | ||||||||||
Executive Committee | ✓ | Financial Expert | ✓ | Technology |
EXPERIENCE AND QUALIFICATIONS
The Board has concluded that Mr. Weaver is qualified to serve on the Board because of his extensive, sophisticated audit and finance experience. Mr. Weaver is designated as a financial expert on the Audit Committee and served as the Chairman until April 2016. Mr. Weaver is a former Vice Chairman of PricewaterhouseCoopers, LLP and was Chairman of its global technology, infocom and entertainment/media practice group.
BOARD EXPERIENCE
Mr. Weaver serves as the Chairman of the Board of Unisys Corporation and Chairman of its Audit Committee. Additionally, Mr. Weaver serves on the Board of WellCare Health Plans, Inc., is Chairman of its Audit Committee, and is a member of its Compensation Committee. He also serves as a member of the Board of Directors of the Statue of Liberty-Ellis Island Foundation, a not-for-profit entity, and serves on its Executive Committee.
AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement 13
PROPOSAL 1: ELECTION OF DIRECTORS |
Douglas D. Wheat
|
Director Since: 1999 | Age: 67 | KEY SKILLS | ||||||||||||
Board of Directors (Chairman) Executive Committee |
✓
|
Healthcare Industry
|
✓
|
Legal and Governance
| ||||||||||
Managing Partner Wheat Investments, LLC |
✓
|
Corporate Finance | ✓ | Strategy | ||||||||||
✓ Mergers & Acquisitions |
EXPERIENCE AND QUALIFICATIONS
The Board has concluded that Mr. Wheat is qualified to serve on the Board because he possesses significant healthcare staffing industry knowledge as well as extensive expertise in corporate finance and mergers and acquisitions. Such knowledge and expertise are critical to the successful design and implementation of our growth strategy. He is currently the Managing Partner of Wheat Investments, a private investment firm. From 2007 to 2015, Mr. Wheat was the founding and Managing Partner of the private equity company Southlake Equity Group. From 1992 until 2006, Mr. Wheat was President of Haas Wheat & Partners. Prior to the formation of Haas Wheat, Mr. Wheat was a founding member of the merchant banking group Donaldson, Lufkin & Jenrette specializing in leveraged buyout financing. From 1974 to 1984, Mr. Wheat practiced corporate and securities law in Dallas, Texas. Mr. Wheat received both his J.D. and B.S. degrees from the University of Kansas.
BOARD EXPERIENCE
Mr. Wheat is the Chairman of the Board of Overseas Shipholding Group and the Chairman of the Board of International Seaways, Inc. He previously served as Vice Chairman of Dex Media, Inc. and as Chairman of SuperMedia prior to its merger with Dex One. Mr. Wheat has also previously served as a member of the Board of Directors of several other companies, including, among others: (1) Playtex Products (of which he also served as Chairman), (2) Dr. Pepper/Seven-Up Companies, Inc., (3) Dr. Pepper Bottling of the Southwest, Inc., (4) Walls Industries, Inc., (5) Alliance Imaging, Inc., (6) Thermadyne Industries, Inc., (7) Sybron International Corporation, (8) Nebraska Book Corporation, (9) ALC Communications Corporation, (10) Mothers Cookies, Inc., and (11) Stella Cheese Company.
THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR THE ELECTION OF EACH OF THE EIGHT DIRECTOR NOMINEES NAMED ABOVE.
|
14 AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement
CORPORATE GOVERNANCE |
Overview of Our Corporate Governance Program
Our Board and executive leaders are stewards of the interests of our shareholders and believe that strong and effective corporate governance is essential to our success. A cornerstone of our corporate governance program is transparent disclosure to our shareholders on a consistent basis. Our approach integrates all components of effective governance, including a strong ethical culture, a comprehensive enterprise risk management program, an ongoing shareholder engagement program, sound financial and legal compliance functions and a commitment to responsibility. Our holistic strategy focuses on delivering long-term shareholder value and has been recognized as producing the highest standards of governance.
The following chart highlights the key aspects of our corporate governance program.
Board Composition
|
Shareholder Rights
|
Key Policies
|
Company Strategy
|
Recognition
| ||||
✓ 88% of Board is Independent | ✓ Shareholder Right to Call a Special Meeting with No Material Restrictions |
✓ Pay-For-Performance Executive Compensation Philosophy |
✓ Five Year Strategic Growth Plan to Expand Workforce Solutions | ✓ #11 of Fortune 100 Fastest Growing Companies (2017) | ||||
✓ Independent Board Chairman | ✓ Proxy Access | ✓ Stock Ownership Guidelines | ✓ Defined and Transparent Long-Term Financial Targets | ✓ Bloomberg Gender- Equality
Index (2017) | ||||
✓ Independent Audit, Governance and Compensation Committees | ✓ Annual Election of Directors & No Staggered Board |
✓ Anti-Hedging Policy | ✓ Recognized Leader and Innovator in Healthcare Workforce Solutions | ✓ Human Rights Campaign Corporate Equality Index (2018) | ||||
✓ Engaged & Diverse Board with 25% Female Directors |
✓ Majority Voting in Uncontested Elections |
✓ Formal Shareholder Engagement Program | ✓ Corporate Social Responsibility Report | ✓ Largest Healthcare Staffing Firm in the U.S. Staffing Industry Analysts (2017) | ||||
✓ Annual Board & Committee Evaluations | ✓ Shareholder Right to Act by Written Consent |
✓ Clawback Policy | ✓ Active Enterprise Risk Management Program | ✓ The Achievers 50 Most Engaged Workplaces (2016) | ||||
✓ Two Financial Experts on the Audit Committee | ✓ No Poison Pill in Effect |
✓ Anti-Pledging Policy | ✓ Annual Ethics & Engagement Survey | ✓ NYSE Governance, Risk and Compliance Leadership Awards (2015) |
In addition to the highlights summarized above, we regularly review, benchmark and update our current corporate governance policies and procedures to ensure best practices. Below are some examples of recent steps we have taken as a result of our efforts to continually evolve our governance program to reflect best practices.
AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement 15
CORPORATE GOVERNANCE |
By taking an integrated approach that focuses on both opportunities and risks, we believe our ESG efforts to date and evolving CSR strategy going forward allow us to proactively address key reputational and operational risks that threaten the sustainability of our business. The illustration below provides a brief summary of some of the CSR efforts we have undertaken to mitigate ESG risks that are relevant to our business.
Our Boards Role in Risk Oversight
18 AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement
CSR EFFORTS & RESULTS ENVIRONMENT LEED Certification Solar Parking Canopies ENERGY STAR-Rated Appliances SMART Corporate-Wide Reduction Strategy Scope 2 or 3 GHG emissions Mass Server Reduction & Energy Consumption Motion Sensor Lighting & Bulb Efficiency Preference for Digital vs. Paper 100% Recycled Paper E-waste through Local Vendors SOCIAL Bloombergs Corporate Equality Index Best and Brightest Companies to Work for HRC Corporate Equality Index Achievers 50 Most Engaged Workplaces (4x) 150 Top Places to Work in Healthcare Training Magazine 2017 Training Top 125 List Leading Ethics and Compliance Programs AMN Healthcare Nursing Scholarship Volunteer Time Off Benefit for Employees GOVERNANCE Separate Chair and CEO 100% of Board Committees are Independent Pay Aligned with Performance Shareholder Right to Call Special Meeting Shareholder Right to Act by Written Consent Proxy Access No Poison Pill Annual Board and Committee Evaluations Majority Voting Standard No Audit Control Deficiencies
CORPORATE GOVERNANCE |
AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement 19
CORPORATE GOVERNANCE |
Board Meetings and Annual Meeting Attendance by Board Members
The table below provides current committee memberships and fiscal year 2017 committee meeting information:
Director | Audit (1) | Compensation (2) |
Corporate Governance (3) |
Executive | ||||
Mark G. Foletta | Chair | |||||||
R. Jeffrey Harris | Member | Member | ||||||
Michael M.E. Johns, M.D. | Member | Chair | ||||||
Martha H. Marsh | Chair | Member | ||||||
Susan R. Salka | Member | |||||||
Andrew M. Stern | Member | Member | ||||||
Paul E. Weaver | Member | Member | ||||||
Douglas D. Wheat | Chair | |||||||
Committee Meetings and Actions by Written Consent | ||||||||
Total Committee Meetings | 9 | 6 | 5 | 2 | ||||
Actions by Written Consent | 0 | 2 | 0 | 1 |
(1) | The Board has determined that all Audit Committee members (A) are financially literate, and (B) meet the criteria for independence set forth in Rule 10A-3 under the Exchange Act, and Section 303A of the NYSE Listed Company Manual. The Board has further determined that Mark G. Foletta and Paul E. Weaver are each an Audit Committee Financial Expert as defined by SEC Rules and Regulations. |
(2) | The Board has determined that all members of the Compensation Committee meet the standards for independence required by the NYSE and the independence requirements of Section 162(m) of the Internal Revenue Code (the Code). |
(3) | The Board has determined that all members of the Corporate Governance Committee meet the standards for independence required by the NYSE. |
22 AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement
CORPORATE GOVERNANCE |
AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement 23
CORPORATE GOVERNANCE |
24 AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement
CORPORATE GOVERNANCE |
Executive Sessions of Non-Management Directors
The Board has executive sessions at each regularly scheduled Board meeting during the year, for which our management director, Ms. Salka, is not present.
Communications with the Board of Directors
The Board has established the following procedure for shareholders and other interested parties to communicate with members of the Board, the presiding director, or the Independent directors as a group. All such communications should be addressed to the attention of our Corporate Secretary at our offices located at 12400 High Bluff Drive, Suite 100, San Diego, California 92130. The Corporate Secretary collects and maintains a log of each such communication and forwards any that the Corporate Secretary believes requires immediate attention to the appropriate members of the Board, who then determine how such communication should be addressed.
AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement 25
DIRECTOR COMPENSATION AND OWNERSHIP GUIDELINES |
AND OWNERSHIP GUIDELINES
Members of the Board, who are not employees of the Company (Independent Directors), receive compensation for their service in the form of cash and equity. Each form of compensation is evaluated by the Compensation Committee on an annual basis. The Compensation Committee believes director pay should be aligned with the long-term interests of shareholders, so it has historically given substantial weight to the equity component, which represented 69% of our Independent Directors median total compensation in 2017. As part of their annual review process, the Compensation Committee evaluates a variety of sources and benchmarks the compensation we pay our Independent Directors against our peer group and relevant market data. It also consults with an independent compensation consulting firm, Frederic W. Cook & CO., Inc. prior to issuing a recommendation to the Board, which it has historically done in April. Following this process provides the Compensation Committee with more visibility into director pay trends based on the most recently disclosed public filings of peer companies included in its analysis. Accordingly, the Compensation Committee has determined that the compensation we pay our Independent Directors falls slightly above the median of our 2017 peer group.
26 AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement
DIRECTOR COMPENSATION AND OWNERSHIP GUIDELINES |
The following table provides information about the compensation that our directors earned during fiscal year 2017. The table does not include Ms. Salka, who received no additional compensation for her service as a director.
Name |
Fees earned or paid in cash ($) |
Stock Awards ($)(1) |
Total ($) |
|||||||||
Mark G. Foletta |
93,750 | 135,021 | 228,771 | |||||||||
R. Jeffrey Harris |
63,750 | 135,021 | 198,771 | |||||||||
Michael M.E. Johns, M.D. |
73,750 | 135,021 | 208,771 | |||||||||
Martha H. Marsh |
78,750 | 135,021 | 213,771 | |||||||||
Andrew M. Stern |
63,750 | 135,021 | 198,771 | |||||||||
Paul E. Weaver |
73,750 | 135,021 | 208,771 | |||||||||
Douglas D. Wheat |
157,500 | 135,021 | 292,521 |
(1) | The amount set forth in this column represents the AGD Fair Value of the 3,365 RSUs we granted each of our directors on April 18, 2017, which will vest on April 18, 2018. |
Director Equity Ownership Requirement
AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement 27
COMPENSATION DISCUSSION AND ANALYSIS |
COMPENSATION DISCUSSION AND ANALYSIS
The following Compensation Discussion and Analysis (CD&A) provides a detailed description of the objectives, philosophy, practices and programs that comprise our named executive officers total rewards program. It also explains how the Compensation Committee determines executive compensation under this program, as it takes great care in the development and refinement of a total rewards program that reflects its stewardship responsibility to AMNs shareholders while simultaneously ensuring the availability of talent to lead our organization to achieve our strategic goals.
More specifically, this CD&A provides clear details related to each of the following aspects of the total rewards program that has been designed for our named executive officers: (1) the objectives and philosophy, (2) the processes and criteria in place for proper oversight, (3) the components of our named executive officers total rewards program, and (4) how each component fits into our Compensation Committees overall objective to support the Companys business strategy.
The Compensation Committee believes that our named executive officers are collectively, a strong, valuable, experienced, skilled and innovative team, with a passion for the Company, its core values and delivering sustainable, long-term returns for our shareholders. Our named executive officers for the 2017 fiscal year are listed below.
NAME | CURRENT TITLE | |
Susan R. Salka |
President and Chief Executive Officer | |
Brian M. Scott |
Chief Financial Officer, Chief Accounting Officer and Treasurer | |
Ralph S. Henderson |
President, Professional Services and Staffing | |
Denise L. Jackson
|
Chief Legal Officer and Corporate Secretary
| |
28 AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement
COMPENSATION DISCUSSION AND ANALYSIS |
Below is a summary relating to the total rewards compensation package we provide our named executive officers.
What We Do | ||
☑ |
Executive Compensation Philosophy. We maintain an Executive Compensation Philosophy, which was reviewed and revised in February 2018, to expressly capture our commitment to equal pay and fostering a culture of ethics.
| |
☑ |
Align Pay with Performance. We align our named executive officer pay with actual total shareholder return and financial performance, with variable pay constituting 73% of our CEOs total compensation and at least half of the total compensation for each of our other named executive officers in 2017.
| |
☑ |
Reward Increases in Shareholder Value. We grant performance restricted stock units (PRSUs) based on absolute and relative total shareholder return (TSR PRSUs) over a three-year performance period, which is intended to reward named executive officers for above-market stock performance (relative to companies in the Russell 2000 Index) or hold them accountable for relatively poor stock performance (relative to companies in the Russell 2000 Index).
| |
☑ |
Grant PRSUs that Focus on Our Long-Term Goals. We grant PRSUs that vest based on our long-term AEBITDA margin goals (AEBITDA PRSUs).
| |
☑ |
Ownership Guidelines. We have meaningful stock ownership requirements for our named executive officers.
| |
☑ |
Cap Incentive Awards. We maintain a cap on annual bonus awards for our named executive officers under our 2017 Senior Executive Management Incentive Bonus Plan (the Bonus Plan).
| |
☑ |
Bonus Awards Based on Objective and Key Financial Metrics. 70% of our Bonus Plan target for each named executive officer is based on achieving our annual revenue and AEBITDA targets, two key financial metrics for the Company. The remaining 30% is based on objective non-financial criteria such as execution on key initiatives.
| |
☑ |
Utilize Independent Compensation Consultant. Our Compensation Committee utilizes the services of an independent and reputable compensation consultant, Frederic W. Cook, to provide recommendations on our named executive officers pay.
| |
☑ |
Responsible Use of Shares. We judiciously grant shares under our The AMN Healthcare 2017 Equity Plan (the Equity Plan), and our share utilization rate under our Equity Plan falls below industry norms.
| |
☑
|
Appropriate Peer Group Selection. We regularly review our designated peer group to ensure that our compensation program is properly aligned with the actual peers with which we compete for talent and business.
|
What We Dont Do | ||
☒ |
No Risky Programs. We do not engage in compensation programs that create undue risk.
| |
☒ |
No Pledges or Hedges of, or Liens on, Our Common Stock. We prohibit the pledging of, or hypothecating, or otherwise placing a lien on, any Common Stock or other equity interests of the Company. We also prohibit hedging.
| |
☒ |
No Employment Contracts Other than with CEO. We do not provide employment contracts other than for our CEO.
| |
☒ |
No New Tax Gross-ups. We have committed to cease entering into new employment or other agreements with tax gross-ups for named executive officers.
| |
☒
|
No Options or SARs. We have not granted equity awards in the form of options or SARs since 2010.
|
AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement 29
COMPENSATION DISCUSSION AND ANALYSIS |
The following charts compare our year-over-year performance on certain financial metrics that we utilized in making compensation decisions for our named executive officers in 2017.
(1) | For more detail regarding our financial results, please see our 2017 annual report on Form 10-K filed by us with the SEC on February 16, 2018 and provided to you concurrently with this proxy statement. We provide the summary financial information in this proxy statement solely to help you in your evaluation and review of our CD&A. It should not be used as a substitute for a review of the detailed financial information in our 2017 annual report on Form 10-K. |
(2) | For information on AEBITDA, which stands for adjusted earnings before interest, taxes, depreciation and amortization, and a reconciliation of it to our 2017 net income, please see Exhibit B to this proxy statement (page B-1). |
(3) | AEBITDA margin represents, as a percentage, AEBITDA divided by consolidated revenue. |
30 AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement
Consolidated revenue (MM) $1,988 $1,902 2016 revenue 2017 revenue 5% yoy growth Consolidated AEBITDA (MM) 12.9% margin 12.5% margin $256.4 $236.9 2016 AEBITDA 2017 AEBITDA 8% yoy growth
COMPENSATION DISCUSSION AND ANALYSIS |
The Compensation Committee placed considerable emphasis on our TSR as well as financial and operational performance over the past 12 months in determining our CEOs 2017 cash bonus as well as her 2017 equity awards. Because certain compensation information included in this proxy statement spans the last three fiscal years, we have set forth below our cumulative total shareholder return and compound annual growth rate for the one-, two- and three-year periods ended December 31, 2017.
Period |
Cumulative Total Shareholder Return (1) |
Compound Annual Growth Rate |
Common Stock Price at Beginning of Period |
|||||||||
One-Year Period Ended December 31, 2017 |
33% | N/A | $ | 38.45 | ||||||||
Two-Year Period Ended December 31, 2017 |
54% | 26% | $ | 31.05 | ||||||||
Three-Year Period Ended December 31,2017 |
165% | 36% | $ | 19.60 |
(1) | The closing price of our Common Stock on December 29, 2017 (the last trading day of the year) was $49.25. Cumulative total shareholder return is the percentage increase in the 90 day average closing price of our Common Stock on the trading day at the end of the relevant investment period from the 90 day average closing price of our Common Stock on the last trading day of the year preceding the beginning of the applicable period. We did not pay any dividends during the periods set forth in this table. |
2017 Compensation for Our Named Executive Officers
Numerous factors influenced our compensation decisions for 2017 with the customary overarching goal of closely linking pay to performance. In 2017, performance-based cash incentives and equity compensation (which is inherently linked to performance) comprised 73% of our CEOs compensation, and 56%63% of the total compensation for each of our other named executive officers.
To illustrate this, the chart set forth below reflects the percentage breakdown of our CEOs 2017 compensation as set forth in the Summary Compensation Table.
As the Compensation Committee has consistently done throughout the past several years, it based its 2017 compensation decisions around financial goal setting for 2017 and other actions influencing executive compensation on
AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement 31
Ceo compensation at risk 5% 22% 14% 59% 73% at risk Salary bonus equity other
COMPENSATION DISCUSSION AND ANALYSIS |
the expectation that (1) we would achieve market-leading revenue and AEBITDA growth on a consolidated basis and within each of our business segments, and (2) our named executive officers would lead their teams to successfully execute our business strategy in a manner that reflected our core values. Due to our solid operational performance and financial results, each named executive officer earned 85% of his or her target bonus that was tied to the Companys 2017 financial performance.
We set forth below the breakdown of each named executive officers compensation for 2017 as taken from the Summary Compensation Table.
Response to 2017 Say-on-Pay Vote
32 AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement
Summary of our Named executive Officers Compensation in 2017
COMPENSATION DISCUSSION AND ANALYSIS |
In 2018, based on discussions with our shareholders and input from the Compensation Committees independent consultant, the Compensation Committee made adjustments to the vesting schedule and maximum payouts of new equity awards to reduce complexity and reflect more common market practices (e.g., a three-year ratable vesting schedule for its time-vested RSUs).
Our Compensation Program Philosophy and Objectives
AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement 33
COMPENSATION DISCUSSION AND ANALYSIS |
34 AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement
COMPENSATION DISCUSSION AND ANALYSIS |
OUR 2017 PEER GROUP
| ||
Amedisys, Inc.
|
Korn/Ferry International
| |
Cross Country Healthcare, Inc.
|
LHC Group, Inc.
| |
Healthcare Services Group, Inc.
|
MEDNAX, Inc.
| |
Tivity Health, Inc.
|
On Assignment, Inc.
| |
Huron Consulting Group Inc.
|
Premier, Inc.
| |
Insperity, Inc.
|
Team Health Holdings, Inc.
| |
Kforce, Inc.
|
TrueBlue, Inc. |
36 AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement
COMPENSATION DISCUSSION AND ANALYSIS |
38 AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement
COMPENSATION DISCUSSION AND ANALYSIS |
Our 2017 Compensation Program and Results
Our named executive officers 2017 direct compensation consisted of: (1) a base salary; (2) cash incentive bonus based on performance; (3) long-term equity incentives and (4) all other compensation, typically ranges from 1%5% of our CEOs total compensation. We discuss each component of our 2017 compensation program for our named executive officers in more detail below.
BASE SALARY
In late 2016, the Compensation Committee reviewed annual base salary levels for the named executive officers, and after careful consideration, approved increases effective January 1, 2017 ranging from three to six percent from the previous year, as set forth in the table immediately to the right. In December 2017, the Compensation Committee considered base salaries of our named executive officers for 2018. In making determinations, the Compensation Committee considers, among other things, peer group benchmarking, individual and company performance.
When benchmarking Ms. Salkas 2017 base salary, it was below the median among other CEOs among our peers.
Named Executive Officer
|
2016 Salary ($)
|
2017 Salary ($)
|
Increase %
|
|||||||||
Susan R. Salka
|
|
790,000
|
|
|
837,400
|
|
|
6
|
| |||
Brian M. Scott
|
|
450,000
|
|
|
465,000
|
|
|
3
|
| |||
Ralph H. Henderson
|
|
450,000
|
|
|
465,000
|
|
|
3
|
| |||
Denise L. Jackson
|
|
375,000
|
|
|
390,000
|
|
|
4
|
|
AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement 39
COMPENSATION DISCUSSION AND ANALYSIS |
BONUS PLAN
Target Bonus. In January 2017, the Compensation Committee reviewed the target bonus level for each named executive officer, which we express as a percentage of annual base salary. After careful consideration of peer group data and other benchmarking information, the Compensation Committee decided to maintain the existing bonus percentage target for Mr. Scott and Ms. Jackson while increasing the target percentage for Ms. Salka and Mr. Henderson.
The table below shows 2017 target bonus information for each named executive officer both in dollar amount and a percentage of salary together with, for comparative purposes, the same figures for 2016.
Named Executive Officer
|
2016 Bonus Target (% of Salary)
|
2017 Bonus Target (% of Salary)
|
2016 Bonus Target ($)
|
2017 Bonus Target ($)
|
||||||||||||
Susan R. Salka
|
|
100
|
|
|
110
|
|
|
790,000
|
|
|
921,140
|
| ||||
Brian M. Scott
|
|
85
|
|
|
85
|
|
|
382,500
|
|
|
395,250
|
| ||||
Ralph S. Henderson
|
|
75
|
|
|
85
|
|
|
337,500
|
|
|
395,250
|
| ||||
Denise L. Jackson
|
|
60
|
|
|
60
|
|
|
225,000
|
|
|
234,000
|
|
We believe that Ms. Salkas 2017 dollar bonus target fell around the median among CEOs within our 2017 executive compensation peer group, which the Compensation Committee believed was appropriate as an incentive since Ms. Salkas base salary fell below the median.
Structure of our Bonus Plan. In 2017, and consistent with previous years, the Financial Component comprised 70% of our named executive officers total target bonuses, and the RP/Leadership Component comprised the remaining 30%. Beginning in 2017, Mr. Hendersons Financial Component bonus is tied to the Companys consolidated annual revenue and AEBITDA goals due to his oversight of businesses within each of our reporting segments.
We tied the Financial Component of the bonus to the achievement of financial targets set forth in the Companys 2017 Annual Operating Plan (the 2017 Ops Plan) that we understood had represented above market growth for our three business segments on a consolidated basis.
In 2017, the weighting of the performance metrics was consistent for each of our named executive officers:
Named Executive Officer
|
Consolidated Revenue
|
Consolidated AEBITDA
|
RP/ Leadership Component
| ||||||||||||
Susan R. Salka
|
|
35%
|
|
|
35%
|
|
|
30%
|
| ||||||
Brian M. Scott
|
|
35%
|
|
|
35%
|
|
|
30%
|
| ||||||
Ralph S. Henderson
|
|
35%
|
|
|
35%
|
|
|
30%
|
| ||||||
Denise L. Jackson
|
|
35%
|
|
|
35%
|
|
|
30%
|
|
40 AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement
COMPENSATION DISCUSSION AND ANALYSIS |
Metric
|
2017 Ops Plan Target
|
2017 Results
|
$ Variance From 2017 Ops Plan Target
|
% Variance From 2017 Ops Plan Target
|
||||||||||||
Consolidated Revenue
|
|
2,050,000
|
|
|
1,988,454
|
|
|
(61,545
|
)
|
|
(3
|
)
| ||||
Pre-Bonus AEBITDA
|
|
262,965
|
|
|
263,411
|
|
|
446
|
|
|
0
|
|
(4) | We use Pre-Bonus Adjusted EBITDA solely to determine bonuses. Pre-Bonus Adjusted EBITDA excludes from Adjusted EBITDA the payment of bonuses and, other extraordinary items not contemplated in the 2017 Ops Plan. We identify this measurement as Pre-Bonus AEBITDA in this proxy statement. Under no circumstances should Pre-Bonus AEBITDA be used to substitute for any other financial metric and is used by us solely to determine bonus amounts. |
AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement 41
COMPENSATION DISCUSSION AND ANALYSIS |
The tables below set forth metrics and summary calculations for each named executive officers bonus amounts under the RP/Leadership Component together with the final amounts under the Financial Component, which makes up 70% of the total bonus amount.
MS. SALKAS BONUS METRICS
|
||||||||||||||||||||||||||||||||
Pre-Bonus AEBITDA
|
Revenue
|
RP/Leadership
|
||||||||||||||||||||||||||||||
Levels
|
% of Target
|
Pre-Bonus AEBITDA ($ in 1000s)
|
Bonus Amount ($)
|
% of Target
|
Revenue ($ in 1000s)
|
Bonus Amount
|
% of Target
|
Target ($)
|
||||||||||||||||||||||||
Maximum
|
|
120
|
|
|
315,558
|
|
|
644,798
|
|
|
110
|
|
|
2,255,000
|
|
|
644,798
|
|
|
200
|
|
|
552,684
|
| ||||||||
Target
|
|
100
|
|
|
262,965
|
|
|
322,399
|
|
|
100
|
|
|
2,050,000
|
|
|
322,399
|
|
|
100
|
|
|
276,342
|
| ||||||||
Threshold
|
|
90
|
|
|
236,668
|
|
|
161,200
|
|
|
90.5
|
|
|
1,855,250
|
|
|
16,120
|
|
|
None
|
|
|
N/A
|
| ||||||||
MS. SALKAS BONUS METRICS ACHIEVED AND BONUS EARNED
|
||||||||||||||||||||||||||||||||
Achieved
|
|
100
|
|
|
263,411
|
|
|
322,399
|
|
|
97
|
|
|
1,988,454
|
|
|
225,679
|
|
|
Not Determined (5)
|
| |||||||||||
Total Bonus Earned: $548,078
|
% of Target Bonus Earned under
|
MR. SCOTTS BONUS METRICS
|
||||||||||||||||||||||||||||||||
Pre-Bonus AEBITDA
|
Revenue
|
RP/Leadership
|
||||||||||||||||||||||||||||||
Levels | % of Target |
Pre-Bonus AEBITDA ($ in 1000s) |
Bonus Amount ($) |
% of Target | Revenue ($ in 1000s) |
Bonus Amount ($) |
% of Target | Target ($) | ||||||||||||||||||||||||
Maximum
|
|
120
|
|
|
315,558
|
|
|
276,675
|
|
|
110
|
|
|
2,255,000
|
|
|
276,675
|
|
|
200
|
|
|
237,150
|
| ||||||||
Target
|
|
100
|
|
|
262,965
|
|
|
138,338
|
|
|
100
|
|
|
2,050,000
|
|
|
138,338
|
|
|
100
|
|
|
118,575
|
| ||||||||
Threshold
|
|
90
|
|
|
236,668
|
|
|
69,169
|
|
|
90.5
|
|
|
1,855,250
|
|
|
6,917
|
|
|
None
|
|
|
N/A
|
| ||||||||
MR. SCOTTS BONUS METRICS ACHIEVED AND BONUS EARNED
|
||||||||||||||||||||||||||||||||
Achieved
|
|
100
|
|
|
263,411
|
|
|
138,338
|
|
|
97
|
|
|
1,988,454
|
|
|
96,836
|
|
|
Not Determined (5)
|
| |||||||||||
Total Bonus Earned: $235,174
|
% of Target Bonus Earned under Financial Component: 85% |
MR. HENDERSONS BONUS METRICS
|
||||||||||||||||||||||||||||||||
Pre-Bonus AEBITDA
|
Revenue
|
RP/Leadership
|
||||||||||||||||||||||||||||||
Levels
|
% of Target
|
Pre-Bonus AEBITDA ($ in 1000s)
|
Bonus Amount ($)
|
% of Target
|
Revenue ($ in 1000s)
|
Bonus Amount ($)
|
% of Target
|
Target ($)
|
||||||||||||||||||||||||
Maximum
|
|
120
|
|
|
315,558
|
|
|
276,675
|
|
|
110
|
|
|
2,255,000
|
|
|
276,675
|
|
|
200
|
|
|
237,150
|
| ||||||||
Target
|
|
100
|
|
|
262,965
|
|
|
138,338
|
|
|
100
|
|
|
2,050,000
|
|
|
138,338
|
|
|
100
|
|
|
118,575
|
| ||||||||
Threshold
|
|
90
|
|
|
236,668
|
|
|
69,169
|
|
|
90.5
|
|
|
1,855,250
|
|
|
6,917
|
|
|
None
|
|
|
N/A
|
| ||||||||
MR. HENDERSONS BONUS METRICS ACHIEVED AND BONUS EARNED
|
||||||||||||||||||||||||||||||||
Achieved
|
|
100
|
|
|
263,411
|
|
|
138,338
|
|
|
97
|
|
|
1,988,454
|
|
|
96,836
|
|
|
Not Determined (5)
|
| |||||||||||
Total Bonus Earned: $235,174
|
% of Target Bonus Earned under Financial Component: 85% |
42 AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement
COMPENSATION DISCUSSION AND ANALYSIS |
MS. JACKSONS BONUS METRICS
|
||||||||||||||||||||||||||||||||
Pre-Bonus AEBITDA
|
Revenue
|
RP/Leadership
|
||||||||||||||||||||||||||||||
Levels
|
% of Target
|
Pre-Bonus AEBITDA ($ in 1000s)
|
Bonus Amount ($)
|
% of Target
|
Revenue ($ in 1000s)
|
Bonus Amount
|
% of Target
|
Target ($)
|
||||||||||||||||||||||||
Maximum
|
|
120
|
|
|
315,558
|
|
|
163,800
|
|
|
110
|
|
|
2,255,000
|
|
|
163,800
|
|
|
200
|
|
|
140,400
|
| ||||||||
Target
|
|
100
|
|
|
262,965
|
|
|
81,900
|
|
|
100
|
|
|
2,050,000
|
|
|
81,900
|
|
|
100
|
|
|
70,200
|
| ||||||||
Threshold
|
|
90
|
|
|
236,668
|
|
|
40,950
|
|
|
90.5
|
|
|
1,855,250
|
|
|
4,095
|
|
|
None
|
|
|
N/A
|
| ||||||||
MS. JACKSONS BONUS METRICS ACHIEVED AND BONUS EARNED
|
||||||||||||||||||||||||||||||||
Achieved
|
|
100
|
|
|
263,411
|
|
|
81,900
|
|
|
97
|
|
|
1,988,454
|
|
|
57,330
|
|
|
Not Determined (5)
|
| |||||||||||
Total Bonus Earned: $139,230
|
% of Target Bonus Earned under Financial Component: 85% |
(5) | As discussed in the narrative above, the Compensation Committee decided to tie the RP/Leadership Component for each named executive officer in 2017 to the implementation of new front and back office enterprise information technology systems across the Companys portfolio. We now anticipate that the new platform will launch in the first half of 2018 in our locum tenens segment. As a result, we will not determine the amount that any named executive officer earns under this component of the 2017 bonus until June 2018, and we will report the amount that we pay under this component, if any, as compensation for 2018. |
LONG-TERM INCENTIVE COMPENSATION
In 2017, the Compensation Committee granted equity awards to each named executive officer and believes it serves as a key component of our named executive officers compensation package. We set forth in the chart below the AGD Fair Value of each equity component granted to each named executive officer.
Named Executive Officer
|
AGD Fair Value of 2017 TSR PRSU Award ($)
|
AGD Fair Value of 2017 AEBITDA PRSU Award ($)
|
AGD Fair Value of 2017 RSU Award ($)
|
Total AGD Fair Value of 2017 Awards ($)
|
||||||||||||
Susan R. Salka
|
|
599,967
|
|
|
699,988
|
|
|
1,000,000
|
|
|
2,299,955
|
| ||||
Brian M. Scott
|
|
209,981
|
|
|
244,994
|
|
|
244,994
|
|
|
699,969
|
| ||||
Ralph S. Henderson
|
|
209,981
|
|
|
244,994
|
|
|
244,994
|
|
|
699,969
|
| ||||
Denise L. Jackson
|
|
122,945
|
|
|
143,516
|
|
|
143,516
|
|
409,978 |
AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement 43
COMPENSATION DISCUSSION AND ANALYSIS |
Relative TSR Percentile Rank
|
% of 2017 TSR PRSUs Earned if Absolute TSR Is Negative (1)
|
% of 2017 TSR PRSUs that Are Earned if Absolute TSR Is Positive
| ||
<25.0%
|
0
|
0
| ||
25.0%
|
12.50
|
25.00
| ||
37.5%
|
31.25
|
62.50
| ||
50.0%
|
100.00
|
100.00
| ||
62.5%
|
100.00
|
137.50
| ||
75.0%
|
100.00
|
175.00
|
(1) | For each one percentile above the 25th percentile, an additional 3% of the TSR PRSUs will be earned if Absolute TSR is positive, and the maximum payout cannot exceed 175%. If Absolute TSR is negative, for each one percentile above the 25th percentile, an additional 1.5% of the TSR PRSUs will be earned up to the 50th percentile with the maximum payout of 100%. |
Named Executive Officer
|
AGD Fair Value of 2016 Equity Awards ($)
|
AGD Fair Value of 2017 Equity Awards ($)
|
Variance Between Value of 2016 and 2017 Equity Awards ($)
|
% Increase Between Value of 2016 and 2017
|
||||||||||||
Susan R. Salka
|
|
2,134,921
|
|
|
2,299,955
|
|
|
165,034
|
|
|
8
|
| ||||
Brian M. Scott
|
|
599,107
|
|
|
699,969
|
|
|
100,862
|
|
|
17
|
| ||||
Ralph S. Henderson
|
|
599,107
|
|
|
699,969
|
|
|
100,862
|
|
|
17
|
| ||||
Denise L. Jackson
|
|
399,407
|
|
|
409,978
|
|
|
10,571
|
|
|
3
|
| ||||
Total
|
|
3,732,542
|
|
|
4,109,871
|
|
|
377,329
|
|
|
10
|
|
(6) | As set forth in the Grant of Plan-Based Awards Table, the target number of TSR PRSUs granted in 2017 for each named executive officer is as follows: (1) for Ms. Salka, 11,829; (2) for Mr. Scott, 4,140; (3) for Mr. Henderson, 4,140; and (4) for Ms. Jackson, 2,424. |
(7) | As set forth in the Grant of Plan-Based Awards Table, the target number of AEBITDA PRSUs granted in 2017 for each named executive officer is as follows: (1) for Ms. Salka, 17,983; (2) for Mr. Scott, 6,294; (3) for Mr. Henderson, 6,294; and (4) for Ms. Jackson, 3,687. |
44 AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement
COMPENSATION DISCUSSION AND ANALYSIS |
RESULTS OF OUR 2015 PRSU AWARDS
ACTUAL CEO PAY
The difference between actual pay and the grant date valuation of our long-term incentive vehicles can be significant. Given the substantial portion of our CEOs compensation that is performance based, we believe it is critical to consider actual pay together with the performance of our Companys Common Stock price. We recognize that companies and proxy advisory firms have used various methodologies to calculate actual and realizable compensation. We also are aware of the SECs proposed pay versus performance disclosure rule released in April 2015 (the Actual Pay Proposed Rule), which, among other things, contemplates disclosure of a CEOs actual pay.
To provide more easily comparable information on these calculations, we have set forth below a table that summarizes the following for our CEO for each of the last three years: (1) her target total direct pay as determined by the Compensation Committee, (2) her total pay as set forth in the Summary Compensation Table and (3) her actual pay based on the Actual Pay Proposed Rule.
(1) | Under the SECs Actual Pay Proposed Rule, as applicable to our CEOs components of compensation for the years set forth in the table, actual pay equals the total compensation set forth in the Summary Compensation Table for the covered year adjusted as follows: (A) we deduct the value of stock awards and options awards set forth in the Summary Compensation Table for the covered year and (B) we add the fair value on the vesting date of all stock awards and option awards for which all applicable vesting conditions were satisfied during the covered fiscal year. For awards that vested on a certain date, but did not actually settle until it was established whether the conditions for acceleration had been met or the applicable performance test had been certified (the Determination Date), the table reflects the value of such shares during the year of vesting but utilizes the fair market value on the Determination Date, which usually is in February and |
AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement 45
CHIEF EXECUTIVE OFFICER PAY CHART 1 2
COMPENSATION DISCUSSION AND ANALYSIS |
approximately two weeks to two months after the vesting date. Any awards deferred by Ms. Salka under our Deferred Compensation Plan are reflected in our calculations. |
(2) | For purposes of calculating Target Pay, this chart utilizes Ms. Salkas target bonus and target equity values preliminarily established by the Compensation Committee for the applicable year, which typically occurs in early January of the subject year or in December prior to the subject year. With respect to the equity target, the amount ultimately granted may vary from what the Compensation Committee actually targeted due to, among other things, the timing of the grant of her RSU equity award. |
Equity Ownership Requirements, Clawback and No Pledging Policies
We maintain meaningful equity ownership requirements as well as clawback and pledging policies to which our named executive officers are subject. We have set forth a summary of these requirements and policies below. Additional details are contained in the Guidelines.
46 AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement
COMPENSATION DISCUSSION AND ANALYSIS |
Overview of Our 2018 Executive Compensation Program
BASE SALARY
The Compensation Committee approved increases in the annual base salaries for the named executive officers for 2018 to maintain a pay for performance alignment, as reflected in the table immediately below.
The base salaries of the named executive officers reflect a 5% to 7% increase as a result of their increased experience, strong individual performance and peer group benchmarking analysis. Our CEOs salary increase for 2018 is also intended to more directly align her salary with CEO pay among our 2018 peer group, where her base salary still falls slightly below the median.
Named Executive Officer
|
2017 Salary ($)
|
2018 Salary ($)
|
% Increase
|
|||||||||
Susan R. Salka
|
|
837,400
|
|
|
900,000
|
|
|
7
|
| |||
Brian M. Scott
|
|
465,000
|
|
|
490,000
|
|
|
5
|
| |||
Ralph S. Henderson
|
|
465,000
|
|
|
490,000
|
|
|
5
|
| |||
Denise L. Jackson
|
|
390,000
|
|
|
409,500
|
|
|
5
|
|
BONUS PLAN
After careful consideration, the Compensation Committee determined that the 2018 bonus target as a percentage of salary should increase for Ms. Salka, Mr. Scott and Mr. Henderson. These increases reflect our excellent performance and strong total shareholder return over the past three years and further incentivize our named executive officers to continue to drive strong financial performance. We set forth below the 2018 target bonuses for each named executive officer as a percentage of salary together with, for comparative purposes, the same figures for 2017.
Named Executive Officer
|
2017 Bonus Target (% of Salary)
|
2018 Bonus Target (% of Salary)
|
||||||
Susan R. Salka
|
|
110
|
|
|
120
|
| ||
Brian M. Scott
|
|
85
|
|
|
100
|
| ||
Ralph S. Henderson
|
|
85
|
|
|
100
|
| ||
Denise L. Jackson
|
|
60
|
|
|
60
|
|
AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement 47
COMPENSATION DISCUSSION AND ANALYSIS |
48 AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement
COMPENSATION COMMITTEE REPORT |
The Compensation and Stock Plan Committee has reviewed and discussed the Compensation Discussion and Analysis with management, and has recommended to the Board that it be included in this proxy statement and our annual report on Form 10-K for the fiscal year ended December 31, 2017.
Compensation and Stock Plan Committee Members
|
Martha H. Marsh
|
R. Jeffrey Harris
|
Michael M.E. Johns, M.D.
|
AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement 49
EXECUTIVE COMPENSATION DISCLOSURE |
EXECUTIVE COMPENSATION DISCLOSURE
Our named executive officers for the 2017 fiscal year are listed below. We provide information regarding the business experience, qualifications and affiliations of our executive officers who are not directors below. For Ms. Salkas experience, qualifications and affiliations, please see page 11 above.
NAME | CURRENT ROLE | |
Susan R. Salka |
President and Chief Executive Officer | |
Brian M. Scott |
Chief Financial Officer, Chief Accounting Officer and Treasurer | |
Ralph S. Henderson |
President, Professional Services and Staffing | |
Denise L. Jackson |
Chief Legal Officer and Corporate Secretary |
Our Non-Director Executive Officers
50 AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement
EXECUTIVE COMPENSATION DISCLOSURE |
The following table shows the compensation earned or accrued by our named executive officers for the three fiscal years ended December 31, 2017, 2016 and 2015.
Named Executive Officer and Position |
Year | Salary ($) (1) |
Bonus ($) |
Stock Awards ($) (2) |
Non-Equity Incentive Plan Compensation ($) (3) |
All Other Compensation ($) (4) |
Total ($) | |||||||||||||||||||||
Susan R. Salka |
2017 | 835,577 | - | 2,299,955 | (5) | 548,078 | 197,357 | 3,880,967 | ||||||||||||||||||||
PEO,(6) President & CEO |
2016 | 788,077 | - | 2,134,921 | (7) | 1,518,775 | 129,567 | 4,571,340 | ||||||||||||||||||||
2015 | 739,154 | - | 1,927,934 | (8) | 1,480,000 | 46,195 | 4,193,283 | |||||||||||||||||||||
Brian M. Scott |
2017 | 464,423 | - | 699,969 | (9) | 235,174 | 84,643 | 1,484,209 | ||||||||||||||||||||
PFO,(10) CFO, CAO & Treasurer |
2016 | 448,846 | - | 599,107 | (11) | 741,094 | 78,062 | 1,867,109 | ||||||||||||||||||||
2015 | 419,231 | 31,500 | 1,443,215 | (12) | 630,000 | 23,368 | 2,547,314 | |||||||||||||||||||||
Ralph S. Henderson |
2017 | 464,423 | - | 699,969 | (9) | 235,174 | 75,587 | 1,475,153 | ||||||||||||||||||||
President, Professional |
2016 | 448,846 | - | 599,107 | (11) | 611,719 | 81,149 | 1,740,821 | ||||||||||||||||||||
Services & Staffing |
2015 | 419,615 | - | 1,443,215 | (12) | 705,600 | 21,484 | 2,589,914 | ||||||||||||||||||||
Denise L. Jackson |
2017 | 389,423 | - | 409,978 | (13) | 139,230 | 49,449 | 988,080 | ||||||||||||||||||||
Chief Legal Officer & Corporate |
2016 | 374,615 | - | 399,407 | (14) | 435,938 | 39,100 | 1,249,060 | ||||||||||||||||||||
Secretary |
2015 | 365,000 | - | 384,850 | (15) | 401,500 | 18,330 | 1,169,680 |
(1) | Salary includes all salary amounts deferred by the named executive officers under the Deferred Compensation Plan. |
(2) | This column reflects the dollar amounts for the years shown of the AGD Fair Value of RSUs and PRSUs granted to our named executive officers. For PRSUs, which are subject to performance conditions, we report the grant date fair value based upon the probable outcome of such conditions and that value is consistent with the estimate of aggregate compensation cost to be recognized over the service period as of the grant date, excluding the effect of estimated forfeitures. For additional information on the valuation assumptions used in the calculation of these amounts, refer to notes 1(o) and 11 to the financial statements included in our annual report on Form 10-K for the fiscal year ended December 31, 2017, as filed with the SEC on February 16, 2018. |
(3) | This column consists of cash awards paid to our named executive officers pursuant to the Bonus Plan. This column sets forth bonus amounts in the year in which they are earned, although we typically pay them in the following fiscal year. |
(4) | This column consists of compensation received by our named executive officers in the form of matching contributions to the Deferred Compensation Plan and Company-paid life insurance premiums. For 2017, we paid matching contributions under the Deferred Compensation Plan as follows: (1) $197,357 for Ms. Salka, which also includes a housing allowance of $32,000 for her relocation to Texas in 2017, (2) $84,643 for Mr. Scott, (3) $75,587 for Mr. Henderson and (4) $49,449 for Ms. Jackson. |
(5) | 20,429 RSUs with an AGD Fair Value of $1,000,000, 11,829 TSR PRSUs with an AGD Fair Value of $599,967 and 17,983 AEBITDA PRSUs with an AGD Fair Value of $699,988, comprise the amount of Ms. Salkas 2017 stock awards. Assuming the highest level of performance conditions will be achieved for the 11,829 TSR PRSU award and the 17,983 AEBITDA PRSU award, the AGD Fair Value of such awards would equal $805,786 and $1,224,970, respectively. |
(6) | PEO refers to our principal executive officer. |
(7) | 29,917 RSUs with an AGD Fair Value of $999,976, 14,143 TSR PRSUs with an AGD Fair Value of $522,442 and 20,295 AEBITDA PRSUs with an AGD Fair Value of $612,503, comprise the amount of Ms. Salkas 2016 stock awards. Assuming the highest level of performance |
AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement 51
EXECUTIVE COMPENSATION DISCLOSURE |
conditions will be achieved for the 14,143 TSR PRSU award and the 20,295 AEBITDA PRSU award, the AGD Fair Value of such awards would equal $746,955 and $1,071,873, respectively. |
(8) | 33,461 RSUs with an AGD Fair Value of $999,982, 17,842 TSR PRSUs with an AGD Fair Value of $438,021 and 25,186 AEBITDA PRSUs with an AGD Fair Value of $489,931 comprise the amount of Ms. Salkas 2015 stock awards. Assuming the highest level of performance conditions will be achieved for the 17,842 TSR PRSU award and the 25,186 AEBITDA PRSU award, the AGD Fair Value of such awards would equal $607,385 and $857,388, respectively. |
(9) | 6,294 RSUs with an AGD Fair Value of $244,994, 4,140 TSR PRSUs with an AGD Fair Value of $209,981 and 6,294 AEBITDA PRSUs with an AGD Fair Value of $244,994 comprise the amount of Mr. Scotts and Mr. Hendersons 2017 stock awards. Assuming the highest level of performance conditions will be achieved for the 4,140 TSR PRSU award and the 6,294 AEBITDA PRSU award, the AGD Fair Value of such awards would equal $282,012 and $428,759, respectively. |
(10) | PFO refers to our principal financial officer. |
(11) | 6,958 RSUs with an AGD Fair Value of $209,992, 4,849 TSR PRSUs with an AGD Fair Value of $179,122 and 6,958 AEBITDA PRSUs with an AGD Fair Value of $209,992 comprise the amount of Mr. Scotts and Mr. Hendersons 2016 stock awards. Assuming the highest level of performance conditions will be achieved for the 4,849 TSR PRSU award and the 6,958 AEBITDA PRSU award, the AGD Fair Value of such awards would equal $256,077 and $367,472, respectively. |
(12) | 8,995 RSUs with an AGD Fair Value of $174,975, 6,372 TSR PRSUs with an AGD Fair Value of $156,433, 8,995 AEBITDA PRSUs with an AGD Fair Value of $174,975, 25,462 PRSUs with an AGD Fair Value of $373,782 and 38,486 PRSUs with an AGD Fair Value of $563,050 comprise the amount of Mr. Scotts and Mr. Hendersons 2015 stock awards. Assuming the highest level of performance conditions will be achieved for the 6,372 TSR PRSU award, the 8,995 AEBITDA PRSU award, the 25,462 PRSU award and the 38,486 PRSU award, the AGD Fair Value of such awards would equal $216,915, $306,202, $495,300 and $748,649, respectively. |
(13) | 3,687 RSUs with an AGD Fair Value of $143,516, 2,424 TSR PRSUs with an AGD Fair Value of $122,945 and 3,687 AEBITDA PRSUs with an AGD Fair Value of $143,516 comprise the amount of Ms. Jacksons 2017 stock awards. Assuming the highest level of performance conditions will be achieved for the 2,424 TSR PRSU award and the 3,687 AEBITDA PRSU award, the AGD Fair Value of such awards would equal $165,120 and $251,144, respectively. |
(14) | 4,639 RSUs with an AGD Fair Value of $140,005, 3,233 TSR PRSUs with an AGD Fair Value of $119,427 and 4,638 AEBITDA PRSUs with an AGD Fair Value of $139,975 comprise the amount of Ms. Jacksons 2016 stock awards. Assuming the highest level of performance conditions will be achieved for the 3,233 TSR PRSU award and the 4,638 AEBITDA PRSU award, the AGD Fair Value of such awards would equal $170,728 and $244,941, respectively. |
(15) | 6,836 RSUs with an AGD Fair Value of $132,977, 4,843 TSR PRSUs with an AGD Fair Value of $118,896 and 6,836 AEBITDA PRSUs with an AGD Fair Value of $132,977 comprise the amount of Ms. Jacksons 2015 stock awards. Assuming the highest level of performance conditions will be achieved for the 4,843 TSR PRSU award and the 6,836 AEBITDA PRSU award, the AGD Fair Value of such awards would equal $164,860 and $232,710, respectively. |
52 AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement
EXECUTIVE COMPENSATION DISCLOSURE |
The following table contains information concerning grants of plan-based awards to our named executive officers under our cash and equity plans during the year ended December 31, 2017.
Name and Type of Equity Award |
Grant Date |
Estimated Future Payouts Plan Awards |
Estimated Future Payouts Under Equity Incentive Plan |
All Other Stock Awards: # of Shares of Stock or Units |
Grant Date Fair Value of Stock Awards ($)(8) |
|||||||||||||||||||||||||||||||
Threshold ($) (2) |
Target ($)(3) |
Maximum ($)(4) |
Threshold (#)(5) |
Target (#)(6) |
Maximum (#)(7) |
|||||||||||||||||||||||||||||||
Susan R. Salka |
189,000 | 1,080,000 | 2,160,000 | |||||||||||||||||||||||||||||||||
TSR PRSU |
1/4/2017 | 1,479 | 11,829 | 20,701 | 599,967 | |||||||||||||||||||||||||||||||
AEBITDA PRSU |
1/4/2017 | 4,496 | 17,983 | 31,470 | 699,988 | |||||||||||||||||||||||||||||||
RSU |
12/19/2017 | 20,429 | (9) | 1,000,000 | ||||||||||||||||||||||||||||||||
Brian M. Scott |
85,750 | 490,000 | 980,000 | |||||||||||||||||||||||||||||||||
TSR PRSU |
1/4/2017 | 518 | 4,140 | 7,245 | 209,981 | |||||||||||||||||||||||||||||||
AEBITDA PRSU |
1/4/2017 | 1,574 | 6,294 | 11,015 | 244,994 | |||||||||||||||||||||||||||||||
RSU |
1/4/2017 | 6,294 | (10) | 244,994 | ||||||||||||||||||||||||||||||||
Ralph S. Henderson |
85,750 | 490,000 | 980,000 | |||||||||||||||||||||||||||||||||
TSR PRSU |
1/4/2017 | 518 | 4,140 | 7,245 | 209,981 | |||||||||||||||||||||||||||||||
AEBITDA PRSU |
1/4/2017 | 1,574 | 6,294 | 11,015 | 244,994 | |||||||||||||||||||||||||||||||
RSU |
1/4/2017 | 6,294 | (10) | 244,994 | ||||||||||||||||||||||||||||||||
Denise L. Jackson |
42,998 | 245,700 | 491,400 | |||||||||||||||||||||||||||||||||
TSR PRSU |
1/4/2017 | 303 | 2,424 | 4,242 | 122,945 | |||||||||||||||||||||||||||||||
AEBITDA PRSU |
1/4/2017 | 922 | 3,687 | 6,452 | 143,516 | |||||||||||||||||||||||||||||||
RSU |
1/4/2017 | 3,687 | (10) | 143,516 |
(1) | The columns comprising the Estimated Future Payouts Under Equity Incentive Plan Awards set forth information regarding our grant of PRSUs to our named executive officers in 2017 of which there were two types given to all: (1) TSR PRSUs based on total shareholder return over a three-period ending on December 31, 2019 and (2) AEBITDA PRSUs based on our 2019 AEBITDA margin. The ultimate number of PRSUs that vest under these awards depends on the results of the TSR Measurement or our 2019 AEBITDA margin, each of which will be calculated approximately three years after the date of grant. We granted all equity awards reflected in this table under the Equity Plan. |
(2) | The amount set forth in this column represents the minimum amount that a named executive officer would receive under our Bonus Plan if we met our 2017 AEBITDA bonus funding threshold (which we set just above our actual 2016 AEBITDA) and the named executive officer met the threshold for 2017 Pre-Bonus AEBITDA. We describe the Bonus Plan, including the 2017 metrics utilized for each named executive officer, in our CD&A above. There is no minimum threshold for a named executive officers RP/Leadership Component under the Bonus Plan, which is why we have not factored in that Component in determining a threshold in this table. |
(3) | The amount set forth in this column represents the amount that a named executive officer would receive under our Bonus Plan if the named executive officer met the target of each metric upon which his or her bonus is based. |
(4) | The Compensation Committee set the maximum bonus for 2017 under the Bonus Plan at 200% of the target amount for each named executive officer. The amount set forth in this column represents the amount that a named executive officer would receive under our Bonus Plan if all financial metrics to which he or she is subject exceeded our target for each metric by 10% to 20% (depending on the metric) and the individual, in the sole discretion of the Compensation Committee, demonstrated superior leadership, made exceptional individual contributions to our success in 2017 and our performance or the performance of the applicable division surpassed that of our direct competitors such that the Compensation Committee awarded him or her the maximum bonus for the RP/Leadership Component. |
(5) | For TSR PRSUs awards, the number of shares set forth in this column assumes that the Relative TSR percentile would equal at least 25%, which establishes the minimum amount of performance that we must achieve for our named executive officers to earn a portion of the award. We describe Relative TSR in our CD&A above. For AEBITDA PRSU awards, the number of shares set forth in this column assumes that our 2019 AEBITDA margin will equal 12.5%. |
(6) | For TSR PRSUs, the number of PRSUs set forth in this column assumes that under the TSR Measurement each of the following conditions has been satisfied: (1) Relative TSR percentile equals 50% and (2) Absolute TSR exceeds zero. For AEBITDA PRSU awards, the number of shares set forth in this column assumes that the 2019 AEBITDA margin will equal 13.5%. |
(7) | The number of TSR PRSUs set forth in this column assumes that under the TSR Measurement each of the following conditions has been satisfied: (1) Relative TSR percentile equals at least 75% and (2) Absolute TSR exceeds zero. For AEBITDA PRSU awards, the number of shares set forth in this column assumes that our 2019 AEBITDA margin will equal or exceed 14.2%. |
(8) | This column represents the grant date fair value, calculated in accordance with SEC rules, of each equity award. For PRSUs, which are subject to performance conditions, we report the grant date fair value based upon the probable outcome of such conditions and that value is consistent with the estimate of aggregate compensation cost to be recognized over the service period as of the grant date, excluding the effect of estimated forfeitures. These amounts do not necessarily correspond to the actual value that will be realized by our named executive officers. For additional information on the valuation assumptions used in the calculation of these amounts, refer to notes 1(o) and 11 to the financial statements included in our annual report on Form 10-K for the fiscal year ended December 31, 2017, as filed with the SEC on February 16, 2018. |
AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement 53
EXECUTIVE COMPENSATION DISCLOSURE |
(9) | The RSUs underlying this award vest on the third anniversary of the grant date, subject to certain accelerated vesting if we achieve our AEBITDA targets in 2018 or 2019. If we meet our 2018 AEBITDA target, 33% of the RSUs will vest on the 13-month anniversary of the grant date. If we meet our 2019 AEBITDA target, 34% of the RSUs will vest on the second anniversary of grant date. |
(10) | The RSUs underlying this award vest on the third anniversary of the grant date, subject to certain accelerated vesting if we achieve our AEBITDA targets in 2017 or 2018. We achieved our 2017 AEBITDA target, and, as a result, 33% of the aggregate RSUs underlying this award vested and settled in February 2018. If we meet our 2018 AEBITDA target, 34% of the aggregate RSUs underlying this award will vest on the second anniversary of the grant date. |
Outstanding Equity Awards at Fiscal Year End
The following table represents equity interests held by the named executive officers as of December 31, 2017, which is comprised of SARs, RSUs and PRSUs awards.
OPTION AWARD (1) | STOCK AWARDS (2) | |||||||||||||||||||||||||||||||||||
Name |
Option Grant |
Number of Securities Underlying Unexercised Options Exercisable |
Option Exercise Price ($) |
Option Expiration Date |
RSU or PRSU Award Grant Date |
Number of Shares or Units of Stock That Have Not Vested |
Market Value of Shares or Units of Stock That Have Not Vested ($) (3) |
Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (3) |
Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($) (3) |
|||||||||||||||||||||||||||
Susan R. Salka | 2/2/2010 | 193,949 | 8.78 | 2/2/2020 | 1/5/2015 | (4) | 31,224 | (5) | 1,537,782 | |||||||||||||||||||||||||||
1/5/2015 | (6) | 44,076 | (7) | 2,170,743 | ||||||||||||||||||||||||||||||||
12/9/2015 | (8) | 11,042 | 1,104,136 | |||||||||||||||||||||||||||||||||
1/5/2016 | (9) | 24,750 | (10) | 1,218,938 | ||||||||||||||||||||||||||||||||
1/5/2016 | (11) | 20,295 | (12) | 999,529 | ||||||||||||||||||||||||||||||||
12/5/2016 | (13) | 29,917 | 1,473,412 | |||||||||||||||||||||||||||||||||
1/4/2017 | (14) | 20,701 | (15) | 1,019,524 | ||||||||||||||||||||||||||||||||
1/4/2017 | (16) | 17,983 | (17) | 885,663 | ||||||||||||||||||||||||||||||||
12/19/2017 | (18) | 20,429 | 1,006,128 | |||||||||||||||||||||||||||||||||
Brian M. Scott | 1/5/2015 | (4) | 11,151 | (5) | 549,187 | |||||||||||||||||||||||||||||||
1/5/2015 | (6) | 15,741 | (7) | 775,224 | ||||||||||||||||||||||||||||||||
1/5/2015 | (19) | 2,969 | 146,223 | |||||||||||||||||||||||||||||||||
1/5/2015 | (21) | 25,462 | (22) | 1,254,004 | ||||||||||||||||||||||||||||||||
1/5/2015 | (23) | 38,486 | (24) | 1,895,436 | ||||||||||||||||||||||||||||||||
1/5/2016 | (20) | 4,662 | 229,604 | |||||||||||||||||||||||||||||||||
1/5/2016 | (9) | 8,486 | (10) | 417,936 | ||||||||||||||||||||||||||||||||
1/5/2016 | (11) | 6,958 | (12) | 342,682 | ||||||||||||||||||||||||||||||||
1/4/2017 | (14) | 7,245 | (15) | 356,816 | ||||||||||||||||||||||||||||||||
1/4/2017 | (16) | 6,294 | (17) | 309,980 | ||||||||||||||||||||||||||||||||
1/4/2017 | (13) | 6,294 | 309,980 | |||||||||||||||||||||||||||||||||
Ralph S. Henderson | 1/5/2015 | (4) | 11,151 | (5) | 549,187 | |||||||||||||||||||||||||||||||
1/5/2015 | (6) | 15,741 | (7) | 775,224 | ||||||||||||||||||||||||||||||||
1/5/2015 | (19) | 2,969 | 146,243 | |||||||||||||||||||||||||||||||||
1/5/2015 | (21) | 25,462 | (22) | 1,254,004 | ||||||||||||||||||||||||||||||||
1/5/2015 | (23) | 38,486 | (24) | 1,895,436 | ||||||||||||||||||||||||||||||||
1/5/2016 | (20) | 4,662 | 229,604 | |||||||||||||||||||||||||||||||||
1/5/2016 | (9) | 8,486 | (10) | 417,936 | ||||||||||||||||||||||||||||||||
1/5/2016 | (11) | 6,958 | (12) | 342,682 | ||||||||||||||||||||||||||||||||
1/4/2017 | (14) | 7,245 | (15) | 356,816 | ||||||||||||||||||||||||||||||||
1/4/2017 | (16) | 6,294 | (17) | 309,980 | ||||||||||||||||||||||||||||||||
1/4/2017 | (13) | 6,294 | 309,980 |
54 AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement
EXECUTIVE COMPENSATION DISCLOSURE |
OPTION AWARD (1) | STOCK AWARDS (2) | |||||||||||||||||||||||||||||||||||
Name |
Option Grant |
Number of Securities Underlying Unexercised Options Exercisable |
Option Exercise Price ($) |
Option Expiration Date |
RSU or PRSU Award Grant Date |
Number of Shares or Units of Stock That Have Not Vested |
Market Value of Shares or Units of Stock That Have Not Vested ($) (3) |
Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (3) |
Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($) (3) |
|||||||||||||||||||||||||||
Denise L. Jackson | 1/5/2015 | (4) | 8,475 | (5) | 417,394 | |||||||||||||||||||||||||||||||
1/5/2015 | (6) | 11,963 | (7) | 589,178 | ||||||||||||||||||||||||||||||||
1/5/2015 | (19) | 2,256 | 111,108 | |||||||||||||||||||||||||||||||||
1/5/2016 | (9) | 5,658 | (10) | 278,657 | ||||||||||||||||||||||||||||||||
1/5/2016 | (11) | 4,638 | (12) | 228,422 | ||||||||||||||||||||||||||||||||
1/5/2016 | (20) | 3,108 | 153,069 | |||||||||||||||||||||||||||||||||
1/4/2017 | (14) | 4,242 | (15) | 208,919 | ||||||||||||||||||||||||||||||||
1/4/2017 | (16) | 3,687 | (17) | 181,585 | ||||||||||||||||||||||||||||||||
1/4/2017 | (13) | 3,687 | 181,585 |
(1) | These columns reflect SARs. |
(2) | These columns consist of RSUs and PRSUs granted under the Equity Plan. |
(3) | The market value of stock awards and the equity incentive plan awards represents (1) the number of shares that had not vested as of December 31, 2017 as set forth in the applicable column, multiplied by (2) $49.25, the closing price of our Common Stock on December 29, 2017 (the last trading day of the year). For PRSUs, the number of shares set forth in the applicable column may be more than the target amount granted under the applicable award as detailed further in the footnotes below, and the amount ultimately received for each such award may be different than the number of shares identified. |
(4) | These PRSUs vested on January 5, 2018. |
(5) | The Compensation Committee performed the TSR Measurement for this award for the measurement period ended December 31, 2017 on January 5, 2018. Relative TSR measured at the 95th percentile and Absolute TSR was positive. Based on those results, the number of PRSUs set forth in this column for this award, which was the maximum amount that could have been received under the award, vested on January 5, 2018. |
(6) | The AEBITDA PRSUs underlying this award vested on January 5, 2018 and settled on February 15, 2018 when the Compensation Committee determined the Companys 2016 AEBITDA margin. |
(7) | Because the number of shares earned under this award was based on the Companys 2017 AEBITDA margin, we set forth the number of shares actually earned. Based on the Companys 2017 AEBITDA margin of 12.9%, the maximum amount for this award was awarded and is set forth in this column. |
(8) | The RSUs underlying this award vest on the third anniversary of the grant date, subject to certain accelerated vesting if we were to achieve our AEBITDA targets in 2016 or 2017. We achieved our 2016 AEBITDA target, and, as a result 33% of the RSUs vested on January 9, 2017 (and are not reflected as unvested in this row). We achieved our 2017 AEBITDA target; accordingly 34% of the original number of RSUs comprising the award vested on the second anniversary of the grant date but did not settle until February 15, 2018, when it was determined that the conditions to acceleration had been met. For purposes hereof, we reflect such shares as vested and do not include them in this row. The amount set forth in this row will vest on December 9, 2018. |
(9) | The TSR PRSUs underlying this award vest on the date on which the Compensation Committee performs the TSR Measurement, which shall occur within 30 days after December 31, 2018. We describe the TSR Measurement in detail in the CD&A section above. |
(10) | The ultimate number of TSR PRSUs that vest under this award depends on the results of the TSR Measurement. The target amount for each of Ms. Salka, Mr. Scott, Mr. Henderson and Ms. Jackson for his or her equity incentive plan award granted on January 5, 2016 is 14,143, 4,849, 4,849 and 3,233, respectively. For the target amount of TSR PRSUs to be earned, Relative TSR under the TSR Measurement would need to equal the 50th percentile and Absolute TSR would have to exceed zero. The range of TSR PRSUs that may be earned by the identified named executive officer under this award is zero to an amount equal to the product of (1) the target amount for such executive, multiplied by (2) 1.75 (the 2016 PRSU Maximum Amount). The threshold amount equals 12.5% of the target amount. If we were to have conducted the TSR Measurement on December 31, 2017 (1) Relative TSR would have measured at the 71st percentile, and (2) Absolute TSR would have been positive. Based on those results, TSR PRSUs equal to 163% of target would have been earned. However, pursuant to the instructions set forth to Item 402(f)(2) of Regulation S-K, we set forth the number of shares representing the 2016 PRSU Maximum Amount for the award in this column. |
(11) | The AEBITDA PRSUs underlying this award vest on January 5, 2019. The settlement date and the determination of the amount of shares actually vested under the award reflected in this row will take place when the Compensation Committee determines our 2018 AEBITDA margin, which we believe will occur in February 2019. |
(12) | Pursuant to the instructions set forth to Item 402(f)(2) of Regulation S-K, which provides that the number of shares reported in this column shall be based on achieving maximum performance goals because our 2017 AEBITDA margin of 12.9% exceeds the 2018 threshold AEBITDA margin of 12.0% but falls below the target AEBITDA margin of 13.0%, we set forth the number of shares representing the target amount for the award in this column. |
(13) | The RSUs underlying this award vest on the third anniversary of the grant date, subject to certain accelerated vesting if we achieve our AEBITDA targets in 2017 or 2018. We met our 2017 AEBITDA target and, accordingly, 33% of the RSUs set forth in this row vested on the 13-month anniversary of the grant date (but are still reflected on this table as unvested because they remained unvested as of December 31, 2017). If we meet our 2018 AEBITDA target, 34% of the RSUs set forth in this row will vest on the second anniversary of the grant date and will settle upon determination that we met our 2018 AEBITDA target in February 2019. |
AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement 55
EXECUTIVE COMPENSATION DISCLOSURE |
(14) | The TSR PRSUs underlying this award vest on the date on which the Compensation Committee performs the TSR Measurement, which shall occur within 30 days after December 31, 2019. We describe the TSR Measurement in detail in the CD&A section above. |
(15) | The ultimate number of TSR PRSUs that vest under this award depends on the results of the TSR Measurement. The target amount for each of Ms. Salka, Mr. Scott, Mr. Henderson and Ms. Jackson for his or her equity incentive plan award granted on January 4, 2017 is 11,829, 4,140, 4,140 and 2,424, respectively. For the target amount of TSR PRSUs to be earned, Relative TSR under the TSR Measurement would need to equal the 50th percentile. The range of TSR PRSUs that may be earned by the identified named executive officer under this award is zero to an amount equal to the product of (1) the target amount for such executive, multiplied by (2) 1.75 (the 2017 PRSU Maximum Amount). The threshold amount equals 12.5% of the target amount. If we were to have conducted the TSR Measurement on December 31, 2017, Relative TSR would have measured at the 73rd percentile, and (2) Absolute TSR would have been positive. Based on those results, TSR PRSUs equal to 169% of the target amount would have been earned. However, pursuant to instructions set forth to Item 402(f)(2) of Regulation S-K, we set forth the number of shares representing the 2017 PRSU Maximum Amount for the award in this column. |
(16) | The AEBITDA PRSUs underlying this award vest on January 4, 2020. The settlement date and the determination of the amount of shares actually vested will take place when the Compensation Committee determines our 2019 AEBITDA margin, which we believe will occur in February 2020. |
(17) | Pursuant to the instructions set forth to Item 402(f)(2) of Regulation S-K, which provides that the number of shares reported in this column shall be based on achieving the target performance goal because our 2017 AEBITDA margin of 12.9% exceeds the 2019 threshold AEBITDA margin of 12.5% but falls below the target AEBITDA margin of 13.5%, we set forth the number of shares representing the target amount for the award in this column. |
(18) | The RSUs underlying this award vest on the third anniversary of the grant date, subject to certain accelerated vesting if we achieve our AEBITDA targets in 2018 or 2019. If we meet our 2018 AEBITDA target, 33% of the RSUs will vest on the 13-month anniversary of the grant date. If we meet our 2019 AEBITDA target, 34% of the RSUs will vest on the second anniversary of grant date. |
(19) | The RSUs reflected in this row vested on January 5, 2018. |
(20) | Approximately 51% of the RSUs set forth in this row vested on the second anniversary of the grant date as a result of accelerated vesting because we achieved our 2017 AEBITDA target. The remaining RSUs will vest on January 5, 2019. |
(21) | The RSUs underlying this grant settled on January 5, 2018. |
(22) | This row reflects a grant that had time-based and performance-based components pursuant to which 12,731 shares of our Common Stock settled on January 5, 2018, and an additional 12,731 shares also settled on such date since the average closing price of our Common Stock during December 2017 exceeded $26.08 per share. Pursuant to the instructions set forth to Item 402(f)(2) of Regulation S-K, which provides that the number of shares reported in this column shall be based on achieving target performance goals (which includes both components) because the average closing price of our Common Stock during December 2017 exceeded the $26.08 per share Common Stock price target that must be met in December 2017 to receive the target amount, we set forth the number of shares representing the target amount for the award in this column. |
(23) | The RSUs underlying this grant will settle on January 5, 2019. |
(24) | This row reflects a grant that has time-based and performance-based components pursuant to which 19,243 shares of our Common Stock will settle on January 5, 2019, and an additional 19,243 shares will settle on such date if the average closing price of our Common Stock during December 2018 equals or exceeds $29.20 per share. Pursuant to the instructions set forth to Item 402(f)(2) of Regulation S-K, which provides that the number of shares reported in this column shall be based on achieving target performance goals (which includes both components) because the average closing price of our Common Stock during December 2017 exceeded the $29.20 per share Common Stock price target that must be met in December 2018 to receive the target amount, we set forth the number of shares representing the target amount for the award in this column. |
Option Exercises and Stock Vested
The following table shows information regarding exercises of option awards to purchase our Common Stock and vesting of stock awards held by our named executive officers during 2017, as of December 31, 2017.
OPTION AWARDS | STOCK AWARDS | |||||||||||||||
Name | Number of Shares Acquired on Exercise (#) |
Value Realized on Exercise ($) |
Number of Shares Acquired on Vesting (#) (1) |
Value Realized on Vesting ($) (2) |
||||||||||||
Susan R. Salka
|
|
-
|
|
|
-
|
|
|
137,999
|
|
|
5,570,281
|
| ||||
Brian M. Scott
|
|
-
|
|
|
-
|
|
|
37,979
|
|
|
1,494,601
|
| ||||
Ralph S. Henderson
|
|
-
|
|
|
-
|
|
|
38,795
|
|
|
1,526,714
|
| ||||
Denise L. Jackson
|
|
-
|
|
|
-
|
|
|
34,847
|
|
|
1,371,351
|
|
(1) | The amount for Ms. Salka in this column includes 112,073 shares of Common Stock underlying vested equity awards that she deferred in 2017. |
(2) | We calculate the Value Realized on Vesting by multiplying (A) the number of shares acquired on vesting and (B) the closing price of our Common Stock on the applicable vest dates. |
56 AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement
EXECUTIVE COMPENSATION DISCLOSURE |
Nonqualified Deferred Compensation
The following table reflects contributions made by the named executive officers and matching contributions made by us under the Deferred Compensation Plan in fiscal year 2017 as well as the named executive officers aggregate earnings, withdrawals and balance information.
NONQUALIFIED DEFERRED COMPENSATION TABLE
Name | Executive Contribution in Last FY ($) (1) |
Registrant Contributions in Last FY ($) (2) |
Aggregate Earnings in Last FY ($) (3) |
Aggregate Withdrawals or Distributions ($) |
Aggregate Balance at FYE ($) (4) |
|||||||||||||||
Susan R. Salka
|
|
4,737,163
|
(5)
|
|
164,805
|
|
|
468,292
|
|
|
-
|
|
|
12,716,925
|
(6)
| |||||
Brian M. Scott
|
|
120,552
|
|
|
84,386
|
|
|
158,039
|
|
|
-
|
|
|
1,056,315
|
| |||||
Ralph S. Henderson
|
|
161,421
|
|
|
75,330
|
|
|
79,021
|
|
|
-
|
|
|
1,331,819
|
| |||||
Denise L. Jackson
|
|
73,817
|
|
|
49,057
|
|
|
213,896
|
|
|
-
|
|
|
1,441,129
|
|
(1) | The 2017 Salary and 2016 Non-Equity Incentive Compensation columns of the Summary Compensation Table include the contributions, as applicable, of the named executive officers set forth in this table. |
(2) | We include the matching contributions made by us set forth in this column in the 2017 All Other Compensation column of the Summary Compensation Table. |
(3) | Aggregate earnings are not reflected in the Summary Compensation Table. Additionally, any changes in the value of Common Stock underlying deferred vested awards are not included in this column. |
(4) | To the extent our named officers made contributions or we made matching contributions to our named executive officers for the periods set forth in the Summary Compensation Table, such amounts are included (subject to increases or decreased earnings on such amounts) in this column. |
(5) | This amount includes the fair market value as of the date of vest of Ms. Salkas deferral of 112,073 shares of Common Stock underlying equity awards that vested in 2017. Ms. Salkas total cash contribution equaled $378,220. |
(6) | This amount includes $8,857,859 representing the value of 179,855 shares of Common Stock underlying Ms. Salkas deferred vested equity awards in her deferred compensation account, which is calculated based on our Common Stock price of $49.25 per share, the closing price on December 29, 2017 (the last trading day of the year). |
AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement 57
EXECUTIVE COMPENSATION DISCLOSURE |
Termination of Employment and Change in Control Arrangements
(7) | Cause is defined in the employment agreement as a termination of employment by us due to Ms. Salkas (i) commission of an act of fraud or embezzlement against us or any of our subsidiaries or conviction in a court of law, or guilty plea or no contest plea, of any charge involving an act of fraud or embezzlement; (ii) conviction in a court of law, or guilty plea or no contest plea, to a felony charge; (iii) willful misconduct as our employee or as an employee for any of our subsidiaries that is reasonably likely to result in injury or financial loss to us or our subsidiaries; (iv) willful failure to render services to us or any of our subsidiaries in accordance with her employment duties, which amounts to a material neglect of duties to us and does not result from physical illness, injury or incapacity, and which failure is not cured promptly after adequate notice; or (v) material breach of certain covenants of the employment agreement, if not cured within 30 days after written notice. |
(8) | Good Reason is defined in the employment agreement as (i) a material breach by us of the employment agreement with the exception of certain provisions thereto not cured within 30 days after the Boards receipt of written notice of such non-compliance; (ii) the assignment to Ms. Salka without her consent of duties materially and adversely inconsistent with her position, duties or responsibilities, or a change in her title or office, or any removal of her from any of such positions, titles or offices, or any failure to elect or reelect her as a member of the Board or any removal of her as such a member, subject to certain exceptions; or (iii) the relocation of our corporate headquarters from San Diego, California of more than 50 miles without her approval. |
(9) | Change in control is defined in the employment agreement as occurring upon: (1) the acquisition by any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act) (a Person) of beneficial ownership (within the meaning of Rule 13d-3 |
58 AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement
EXECUTIVE COMPENSATION DISCLOSURE |
promulgated under the Exchange Act) of a majority of the combined voting power of our then outstanding voting securities entitled to vote generally in the election of directors; (2) our dissolution or liquidation; (3) the sale of all or substantially all of our business or assets; or (4) the consummation of a merger, consolidation or similar form of corporate transaction involving the Company that requires the approval of our shareholders, whether for such transaction or the issuance of securities in the transaction (a Business Combination), if immediately following such Business Combination: (x) a Person is or becomes the beneficial owner, directly or indirectly, of a majority of the combined voting power of the outstanding voting securities eligible to elect directors of the Parent Corporation (or, if there is no Parent Corporation, the Surviving Corporation), or (y) our shareholders cease to beneficially own, directly or indirectly, in substantially the same proportion as they owned the then outstanding voting securities immediately prior to the Business Combination, a majority of the combined voting power of the outstanding voting securities eligible to elect directors of the Parent Corporation (or, if there is no Parent Corporation, the Surviving Corporation). Surviving Corporation means the corporation resulting from a Business Combination, and Parent Corporation means the ultimate parent corporation that directly or indirectly has beneficial ownership of a majority of the combined voting power of the then outstanding voting securities of the Surviving Corporation entitled to vote generally in the election of directors. |
The following table sets forth illustrative examples of the payments and benefits Ms. Salka would have received if any of the circumstances described above occurred as of December 31, 2017.
TERMINATION OF EMPLOYMENT AND CHANGE IN CONTROL ARRANGEMENTS CHIEF EXECUTIVE OFFICER
Termination Reason | Cash Severance ($) |
Bonus ($) | Benefits ($) (1) |
Value of Accelerated Equity Awards ($) (2) |
Tax Gross- Up ($) (3) |
TOTAL ($) | ||||||||||||||||||
Termination of Employment by Us without Cause or by Ms. Salka for Good Reason Absent a Change in Control | 1,674,800 | 2,364,569 | 60,379 | - | - | 4,099,748 | ||||||||||||||||||
Death or Disability | 1,674,800 | 1,182,284 | 15,726 | - | - | 2,872,810 | ||||||||||||||||||
Termination of Employment by Us without Cause or by Ms. Salka for Good Reason with a Change in Control | 2,512,200 | 3,546,853 | 60,379 | 11,297,211 | 6,885,422 | 24,302,065 |
(1) | Under the terms of Ms. Salkas employment agreement, she and her eligible dependents may continue to participate for two years in our medical, life, dental and disability insurance plans to the extent such plans permit continued participation (with Ms. Salka continuing to pay premiums in respect of such coverage that she was paying prior to termination). For purposes of this column, we assume that all plans would permit continued participation and that Ms. Salka (or her eligible dependents in the event of her death) would continue to participate. We value the benefit at our estimated cost of two years of her and her dependents continued participation in the applicable plans. |
(2) | We computed the value of accelerated equity awards using a share price of $49.25, the closing price of our Common Stock on December 29, 2017, the last trading day of the year. This column does not reflect awards that had already vested as of December 31, 2017. As set forth in the applicable equity award agreements, for TSR PRSUs, we have utilized the number of shares Ms. Salka would have received if the applicable TSR Measurements were performed on December 31, 2017; for AEBITDA PRSUs we have utilized the target number underlying the awards based on 2018 or 2019 AEBITDA margin and for the award based on 2017 AEBITDA margin we have utilized the amount she would have received based on our 2017 AEBITDA margin. |
(3) | We calculated the tax gross-up amount based on a number of assumptions, and that amount includes the amount of the 20% excise tax plus the highest federal and California marginal income tax rates and Medicare tax of 1.45%. |
AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement 59
EXECUTIVE COMPENSATION DISCLOSURE |
The following table sets forth illustrative examples of the payments and benefits Mr. Scott, Mr. Henderson and Ms. Jackson would have received if any of the circumstances described above occurred as of December 31, 2017.
TERMINATION OF EMPLOYMENT AND CHANGE IN CONTROL ARRANGEMENTS OTHER EXECUTIVE OFFICERS
BRIAN M. SCOTT | ||||||||||||||||||||
Termination Reason |
Cash Severance ($) |
Bonus ($) |
Benefits ($) |
Value of Accelerated Equity Awards ($)(1) |
TOTAL ($) |
|||||||||||||||
Involuntary Absent a Change in Control | 465,000 | 535,423 | 17,268 | - | 1,017,691 | |||||||||||||||
Involuntary Within One Year of a Change in Control | 930,000 | 1,070,845 | 17,268 | 6,546,113 | 8,564,226 | |||||||||||||||
RALPH S. HENDERSON | ||||||||||||||||||||
Termination Reason |
Cash Severance ($) |
Bonus ($) |
Benefits ($) |
Value of Accelerated Equity Awards ($)(1) |
TOTAL ($) |
|||||||||||||||
Involuntary Absent a Change in Control | 465,000 | 517,498 | 7,863 | - | 990,361 | |||||||||||||||
Involuntary Within One Year of a Change in Control | 930,000 | 1,034,995 | 7,863 | 6,546,113 | 8,518,971 | |||||||||||||||
DENISE L. JACKSON | ||||||||||||||||||||
Termination Reason |
Cash Severance ($) |
Bonus ($) |
Benefits ($) |
Value of Accelerated Equity Awards ($)(1) |
TOTAL ($) |
|||||||||||||||
Involuntary Absent a Change in Control | 390,000 | 325,556 | 4,533 | - | 720,089 | |||||||||||||||
Involuntary Within One Year of a Change in Control | 780,000 | 651,112 | 4,533 | 2,323,566 | 3,759,211 |
(1) | Pursuant to the terms of the equity award agreements with our named executive officers, upon a change in control of the Company, all of their unvested equity awards become vested and exercisable regardless of whether there is a termination of employment. We have included the value of accelerated vesting of each named executive officers equity awards in the table above. For this purpose, we used $49.25, the closing price of our Common Stock on December 29, 2017, the last trading day of the year. This column does not reflect awards that had already vested as of December 31, 2017. As set forth in the applicable equity award agreements, for TSR PRSUs, we have utilized the number of shares the named executive officers would have received if the applicable TSR Measurements were performed on December 31, 2017; for AEBITDA PRSUs we have utilized the target number underlying the awards based on 2018 or 2019 AEBITDA margin and for the award based on 2017 AEBITDA margin we have utilized the amount the executive would have received based on our 2017 AEBITDA margin. For the Special Equity Awards, we utilized the number of shares of Common Stock set forth for such Awards in the table entitled Outstanding Equity Awards at Fiscal Year End. |
60 AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement
EXECUTIVE COMPENSATION DISCLOSURE |
AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement 61
PROPOSAL 2: ADVISORY VOTE ON EXECUTIVE COMPENSATION |
ADVISORY VOTE ON EXECUTIVE
COMPENSATION
THE BOARD UNANIMOUSLY RECOMMENDS A VOTE FOR THE APPROVAL OF THE COMPENSATION OF OUR NAMED EXECUTIVE TO THE COMPENSATION DISCLOSURE RULES OF THE SEC.
|
62 AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement
PROPOSAL 3: RATIFICATION OF THE SELECTION OF OUR INDEPENDENT PUBLIC ACCOUNTING FIRM |
RATIFICATION OF THE SELECTION OF OUR INDEPENDENT PUBLIC ACCOUNTING FIRM
THE BOARD RECOMMENDS A VOTE FOR THE
RATIFICATION OF THE
|
64 AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement
PROPOSAL 4: SHAREHOLDER PROPOSAL |
THE BOARD UNANIMOUSLY RECOMMENDS A VOTE AGAINST THE
SHAREHOLDER PROPOSAL
66 AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement
SECURITY OWNERSHIP AND OTHER MATTERS |
SECURITY OWNERSHIP AND OTHER MATTERS
Security Ownership of Certain Beneficial Owners and Management
Name | Number of Shares of Common Stock Beneficially Owned |
Percent of Class |
||||||
BlackRock, Inc. (1) | 5,934,876 | 12.41 | % | |||||
The Vanguard Group (2) | 4,451,649 | 9.31 | % | |||||
Susan R. Salka (3) (4) | 402,109 | * | ||||||
R. Jeffrey Harris (4) (5) | 129,008 | * | ||||||
Andrew M. Stern (7) | 91,621 | * | ||||||
Michael M.E. Johns, M.D. (8) | 90,708 | * | ||||||
Paul E. Weaver (4) (6) | 89,287 | * | ||||||
Martha H. Marsh (4) (9) | 83,105 | * | ||||||
Brian M. Scott (10) | 68,865 | * | ||||||
Douglas D. Wheat (11) | 38,103 | * | ||||||
Mark G. Foletta (12) | 31,487 | * | ||||||
Denise L. Jackson (10) | 26,952 | * | ||||||
Ralph S. Henderson (10) | 21,833 | * | ||||||
All directors, director nominees and executive officers as a group | 1,073,078 | 2.18 | % |
* | Less than 1%. |
(1) | Of the 5,934,876 shares of Common Stock BlackRock, Inc. beneficially owns, it has sole voting power over 5,839,163 shares of Common Stock and sole dispositive power over all such shares. BlackRock, Inc.s address is 55 East 52nd Street, New York, NY 10055. Ownership amount and other information contained in this table and accompanying footnote for BlackRock, Inc., including voting power and dispositive power information, are based solely on information contained in the Schedule 13G/A (Amendment No. 9) filed by BlackRock, Inc. with the SEC on January 23, 2018. |
(2) | Of the 4,451,649 shares of Common Stock The Vanguard Group (Vanguard) beneficially owns, it has sole voting power over 92,163 shares, shared voting power over 7,117 shares, sole dispositive power over 4,356,669 shares and shared dispositive power over 94,980 shares. Vanguards address is 100 Vanguard Blvd., Malvern, Pennsylvania 19355. Ownership amount and other information contained in this table and accompanying footnote for Vanguard, including voting power and dispositive power information, are based solely on information contained in the Schedule 13G/A (Amendment No. 2) filed by Vanguard with the SEC on February 8, 2018. |
(3) | Includes (A) 238,070 shares of Common Stock owned directly by Ms. Salka and (B) 164,039 shares of Common Stock deemed to be beneficially owned by reason of the right to acquire such shares within 60 days following the Record Date, which are shares she had a right to receive on the Record Date if she exercised all 193,949 of her vested SARS on the Record Date. Ms. Salka also has 42,096 vested PRSUs for which she has deferred receipt under our Deferred Compensation Plan until January 2, 2019, and 90,201 vested RSUs that are deferred until her separation from service. Under the terms of the applicable award agreements, if Ms. Salka is a specified employee within the meaning of Section 409A of the Code, which she is, the distribution of her Common Stock would be delayed six months and one day. Accordingly, we have not included her 132,297 deferred vested RSUs and PRSUs in the table above because she would have no right to receive such shares within 60 days of the Record Date even if her employment with us terminated on the Record Date. If we were to include such amounts, the number of shares beneficially owned by her as set forth in this table would be increased by the corresponding amount. |
AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement 67
SECURITY OWNERSHIP AND OTHER MATTERS |
(4) | Certain named executive officers and directors have vested equity awards in the form of SARs. Under our SARs, grantees have the right to acquire an amount of our Common Stock equal in value to the difference between the fair value of our Common Stock on the date of exercise less the grant price. This table reflects the gross number of shares of Common Stock that the applicable named executive officer or director had the right to acquire on the Record Date based on (A) the fair value of our Common Stock on the Record Date, which equaled $56.90, and (B) the presumed exercise of all SARS that have vested or will vest within 60 days of the Record Date for such individual. The range of grant prices of our outstanding SARs for our named executive officers and our directors is $5.32 to $8.83 (the SAR Grant Price Range). The number of vested SARs held by our directors (no director has unvested SARs) and their respective SAR Grant Price Range are as follows: |
Director | # of Vested SARs on the Record |
SAR Grant Price Range ($) |
||||||
R. Jeffrey Harris | 16,448 | 6.00 to 8.83 | ||||||
Martha H. Marsh | 5,397 | 5.32 | ||||||
Paul E. Weaver | 16,448 | 6.00 to 8.83 |
Additionally, in accordance with our policy, directors and named executive officers are not permitted to pledge, hypothecate or otherwise place liens on any equity securities of the Company that they own (or to engage in any hedging transactions involving our equity securities). Accordingly, no shares of Common Stock identified as beneficially owned in this table by our named executive officers and directors are pledged as security.
(5) | Includes (A) 76,600 shares of Common Stock owned directly by Mr. Harris and (B) 52,408 shares of Common Stock deemed to be beneficially owned by reason of the right to acquire such shares within 60 days following the Record Date, which 52,408 shares consist of (i) 14,305 shares of Common Stock that he has a right to receive on the Record Date if he exercised all 16,448 of his vested SARs on the Record Date, (ii) 34,738 shares of Common Stock underlying vested RSUs for which receipt has been deferred until his separation from service and (iii) 3,365 shares of Common Stock underlying RSUs that will vest within 60 days of the Record Date. |
(6) | Includes (A) 39,657 shares of Common Stock owned directly by Mr. Weaver and (B) 49,630 shares of Common Stock deemed to be beneficially owned by reason of the right to acquire such shares within 60 days following the Record Date, which 49,630 shares consist of (i) 14,305 shares of Common Stock that he has a right to receive on the Record Date if he exercised all 16,448 of his vested SARs on the Record Date, (ii) 31,960 shares of Common Stock underlying vested RSUs for which receipt has been deferred until his separation from service and (iii) 3,365 shares of Common Stock underlying RSUs that will vest within 60 days of the Record Date. |
(7) | Includes (A) 6,668 shares of Common Stock owned directly by Mr. Stern and (B) 84,953 shares of Common Stock deemed to be beneficially owned by reason of the right to acquire such shares within 60 days following the Record Date, which 84,953 shares consist of (i) 81,588 shares of Common Stock underlying vested RSUs for which receipt has been deferred until his separation from service and (ii) 3,365 shares of Common Stock underlying RSUs that will vest within 60 days of the Record Date. |
(8) | Includes (A) 46,418 shares of Common Stock owned directly by Dr. Johns and (B) 44,290 shares of Common Stock deemed to be beneficially owned by Dr. Johns by reason of the right to acquire such shares within 60 days following the Record Date, which 44,290 shares consist of (i) 40,925 shares of Common Stock underlying vested RSUs for which receipt has been deferred until his separation from service and (ii) 3,365 shares of Common Stock underlying RSUs that will vest within 60 days of the Record Date. |
(9) | Includes (A) 45,998 shares of Common Stock owned directly by Ms. Marsh and (B) 37,107 shares of Common Stock deemed to be beneficially owned by reason of the right to acquire such shares within 60 days following the Record Date, which 37,107 shares of Common Stock consist of (i) 4,892 shares of Common Stock that she has a right to receive on the Record Date if she exercised all 5,397 of her vested SARs on the Record Date, (ii) 28,850 shares of Common Stock underlying vested RSUs for which receipt has been deferred until her separation from service and (iii) 3,365 shares of Common Stock underlying RSUs that will vest within 60 days of the Record Date. |
(10) | All shares of Common Stock reflected in this row are owned directly by the named executive officer. |
(11) | Includes 38,103 shares of Common Stock deemed to be beneficially owned by Mr. Wheat by reason of the right to acquire such shares within 60 days following the Record Date, which 38,103 shares consist of (A) 34,738 shares of Common Stock underlying vested RSUs for which receipt has been deferred until his separation from service and (B) 3,365 shares of Common Stock underlying RSUs that will vest within 60 days of the Record Date. |
(12) | Includes (A) 3,525 shares of Common Stock owned directly by Mr. Foletta and (B) 27,962 shares of Common Stock deemed to be beneficially owned by Mr. Foletta by reason of the right to acquire such shares within 60 days following the Record Date, which 27,962 shares consist of (i) 24,597 shares of Common Stock underlying vested RSUs for which receipt has been deferred until his separation from service and (ii) 3,365 shares of Common Stock underlying RSUs that will vest within 60 days of the Record Date. |
Section 16(a) Beneficial Ownership Reporting Compliance
68 AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement
SECURITY OWNERSHIP AND OTHER MATTERS |
Shareholder Proposals for the 2019 Annual Meeting of Shareholders
Delivery of Proxy Statement, Annual Report or Notice of Internet Availability
The Board does not know of any other matter that will come before the Annual Meeting other than those described in this proxy statement. If any other matters properly come up before the Annual Meeting, the persons named in the form of proxy intend to vote all proxies in accordance with their judgment on such matters.
AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement 69
EXHIBIT A TO PROXY STATEMENT |
We may require any shareholder nominee to furnish such other information as we may reasonably require to determine the eligibility of the shareholder nominee to serve as one of our directors.
A-2 AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement
EXHIBIT B TO PROXY STATEMENT |
Non-GAAP Reconciliation for Consolidated AEBITDA For Purposes of 2017 Bonus Achievement
(in thousands) | Year Ended December 31, |
|||
Revenue | ||||
Nurse and allied solutions |
$ | 1,238,543 | ||
Locum tenens solutions |
430,615 | |||
Other workforce solutions |
319,296 | |||
|
|
|||
$ | 1,988,454 | |||
|
|
|||
Segment operating income (1) | ||||
Nurse and allied solutions |
$ | 182,792 | ||
Locum tenens solutions |
51,422 | |||
Other workforce solutions |
81,154 | |||
|
|
|||
315,368 | ||||
Unallocated corporate overhead (2) | 58,954 | |||
|
|
|||
AEBITDA (3) | $ | 256,414 | ||
Depreciation and amortization | 32,279 | |||
Share-based compensation | 10,237 | |||
Acquisition and integration costs | 1,458 | |||
Interest expense, net, and other | 19,677 | |||
Income from operations before income tax | 192,763 | |||
Income tax expense | 60,205 | |||
|
|
|||
Net income | $ | 132,558 | ||
|
|
|||
(in thousands) | Year Ended December 31, |
|||
AEBITDA | $ | 256,414 | ||
Adjustments (4) | 6,997 | |||
|
|
|||
Pre Bonus AEBITDA (5) | $ | 263,411 | ||
|
|
|||
(1) | Segment operating income represents net income plus interest expense (net of interest income) and other, income tax expense, depreciation and amortization, unallocated corporate overhead, acquisition and integration costs and share-based compensation expense. |
(2) | Please note that the amount set forth in this line item excludes the amount set forth in the line item below entitled acquisition and integration costs. Acquisition and integration costs are a subset of unallocated corporate overhead. |
(3) | AEBITDA represents net income plus interest expense (net of interest income) and other, income tax expense, depreciation and amortization, acquisition and integration costs, and share-based compensation expense. Management believes that AEBITDA provides an effective measure of our results, as it excludes certain items that management believes are not indicative of our operating performance and considers measures used in credit facilities. AEBITDA is not intended to represent cash flows for the period, nor has it been presented as an alternative to income from operations or net income as an indicator of operating performance. Although management believes that some of the items excluded from AEBITDA are not indicative of our operating performance, these items do impact the statement of comprehensive income, and management therefore utilizes AEBITDA as an operating performance measure in conjunction with GAAP measures such as net income. |
(4) | The amount represents the adjustments to Adjusted EBITDA decided by the Compensation Committee for bonus calculation and payout only. In establishing Pre-Bonus Adjusted EBITDA targets at the beginning of the year, the Compensation Committee excludes from Adjusted EBITDA, the payout of bonuses and other extraordinary items not contemplated in the Companys 2017 Ops Plan that should be excluded for bonus purposes. |
(5) | Pre-bonus AEBITDA represents the adjustments made to AEBITDA decided by the Compensation Committee. |
AMN HEALTHCARE SERVICES, INC. ï 2018 Proxy Statement B-1
OUR ASPIRATION
We strive to be recognized as one of the most trusted, innovative, and influential forces in helping healthcare organizations provide a quality patient care experience that is more human, more effective, and more achievable.
OUR MISSION
Every day, we...
| Deliver the best talent and insights to help healthcare organizations optimize their workforce |
| Give healthcare professionals opportunities to do their best work towards quality patient care |
| Create a values-based culture of innovation where our team members can achieve their goals |
Fortune 100 Fastest Growing Companies #11
2018 Human Rights Campaign Corporate Equality Index
2018 Bloomberg Gender-Equality Index
NYSE Governance Services Leadership
2016 Exemplary Compensation Discussion and Analysis (CD&A)
2015 Best Governance, Risk and Compliance Program at Small to Mid-Cap Company
Corporate Secretary
2015 Best Compliance & Ethics Program
2015 Corporate Governance Team of the Year
Staffing Industry Analysts
Largest Temporary Healthcare Staffing Firm in the U.S.
#1 Travel Nurse Staffing Provider in the U.S.
#1 Allied Healthcare Staffing Provider in the U.S.
HRO Today
2016 Partnership in Staffing Excellence
2017 Partnership in Recruiting Excellence
Achievers 50 Most Engaged Workplaces
Beckers Hospital Review Top 150 Places to Work in Healthcare
National Best & Brightest Companies to Work For
AMNHealthcare.com | NYSE: AMN | Toll Free: (866) 871-8519
©2018 AMN Healthcare AMN 18 C001
OUR VALUES CONTINUOUS IMPROVEMENT PASSION INNOVATION CUSTOMER FOCUS TRUST RESPECT
ANNUAL MEETING OF SHAREHOLDERS OF AMN HEALTHCARE SERVICES, INC.
Date: Wednesday, April 18, 2018 Time: 8:30 A.M. (Central Time)
Place: 8840 Cypress Waters
Blvd., Suite 300, Dallas, Texas 75019
Please make your marks like this: Use dark black pencil or pen only
The Board of Directors recommends you vote FOR the election of each of the following eight director nominees listed below:
1: Election of Directors Recommends Board
For Against Abstain
01 Mark G. Foletta FOR
02 R. Jeffrey Harris FOR
03 Michael M.E. Johns, M.D. FOR
04 Martha H. Marsh FOR
05 Susan R. Salka FOR
06 Andrew M. Stern FOR
07 Paul E. Weaver FOR
08 Douglas D. Wheat FOR
The Board of Directors recommends you vote FOR proposal 2:
Board
For Against Abstain Recommends
2: To the approve, compensation by non of -binding the
Companys advisory named vote, FOR executive officers
The Board of Directors recommends you vote FOR proposal 3:
Board
For Against Abstain Recommends
3: To ratify the appointment of KPMG LLP as the Companys independent registered public FOR
December accounting 31, firm 2018 for the fiscal year ending
The Board of
Directors recommends you vote AGAINST proposal 4: Board
For Against Abstain Recommends
4: A shareholder proposal entitled: Special
Shareowner Meetings Improvement
AGAINST business Note: In their as may discretion, properly the come proxies before are the authorized Annual Meeting to vote upon or any such adjournment other or postponement of the Annual Meeting.
Authorized Signatures - This section must be completed for your Instructions to be executed.
Please Sign Here Please Date Above
Please Sign Here Please Date Above
Please sign exactly as your name(s) appear(s) on your proxy card. If held in joint tenancy, all persons should sign. Trustees, administrators, etc., should include
title and authority. Corporations should provide full name of the corporation and title of authorized officer signing the proxy.
Please separate carefully at the
perforation and return just this portion in the envelope provided.
Annual Meeting of Shareholders of AMN Healthcare Services, Inc. to be held on Wednesday, April
18, 2018 for holders of common stock as of February 21, 2018
This proxy is being solicited on behalf of the Board of Directors
VOTE BY:
INTERNET TELEPHONE
Call www.proxypush.com/AMN 866-892-1716
Cast your vote online.
OR Use any touch-tone telephone.
View Meeting Documents. Have your Proxy
Card/Voting
Instruction Form ready.
Follow the recorded
instructions.
MAIL
Mark, sign and date your Proxy Card/Voting
Instruction Form.
Detach your Proxy Card/Voting Instruction Form.
Return your Proxy Card/Voting Instruction Form in the postage-paid envelope provided.
All votes must be received by 5:00 P.M., Eastern Time, on April 17, 2018, the day before the Annual Meeting.
The undersigned hereby appoints Douglas D. Wheat, Andrew M. Stern and Paul E. Weaver, and each or either of them, as the true and lawful attorneys of the undersigned, with full
power of substitution and revocation, and authorizes them, and each of them, to vote all the shares of Common Stock of AMN Healthcare Services, Inc. (the Company) which the undersigned is entitled to vote at Annual Meeting of
Shareholders of the Company and any adjournment or postponement thereof upon the matters specified and upon such other matters as may be properly brought before the Annual Meeting or any adjournment thereof, conferring authority upon such true and
lawful attorneys to vote in their discretion on such other matters as may properly come before the Annual Meeting and any adjournment or postponement thereof, and revoking any proxy heretofore given.
THE SHARES REPRESENTED BY THIS PROXY WILL BE VOTED AS DIRECTED OR, IF NO DIRECTION IS GIVEN, SHARES WILL BE VOTED FOR THE ELECTION OF EACH OF THE EIGHT DIRECTOR
NOMINEES LISTED IN PROPOSAL 1, FOR PROPOSALS 2 AND 3 AND AGAINST PROPOSAL 4.
PROXY TABULATOR FOR
AMN HEALTHCARE SERVICES, INC. P.O. BOX 8016 CARY, NC 27512-9903
EVENT #
CLIENT #
Proxy AMN Healthcare Services, Inc. Annual Meeting of Shareholders April 18, 2018 at 8:30 a.m. (Central Time) This Proxy is Solicited on Behalf of the Board of Directors The undersigned, revoking all previous proxies, hereby appoints Douglas D. Wheat, Andrew M. Stern and Paul E. Weaver (collectively, the Named Proxies), or any of them, as attorneys and proxies with full power of substitution and resubstitution to represent the undersigned and to vote all shares of Common Stock of AMN HEALTHCARE SERVICES, INC. (the Company), the undersigned is entitled to vote at the Annual Meeting of Shareholders of the Company, or any adjournment or postponement thereof, to be held at the 8840 Cypress Waters Boulevard Suite 300, Dallas, Texas 75019, on April 18, 2018 at 8:30 a.m. Central Time and all adjournments thereof. The purpose of the Annual Meeting is to take action on the following: 1. Proposal 1: To elect Directors. 2. Proposal 2: To approve, by a non-binding advisory vote, the compensation of the Companys named executive officers. 3. Proposal 3: To ratify the appointment of KPMG LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2018. 4. Proposal 4: A shareholder proposal entitled: Special Shareowner Meetings Improvement, if properly presented. The Company may also transact such other business as may properly come before the Annual Meeting or any adjournment or postponement of the Annual Meeting. The eight directors up for re-election are: Mark G. Foletta, R. Jeffrey Harris, Michael M.E. Johns, M.D., Martha H. Marsh, Susan R. Salka, Andrew M. Stern, Paul E. Weaver and Douglas D. Wheat. The Board of Directors of the Company recommends a vote FOR the election of the eight director nominees listed in proposal 1, FOR proposals 2 and 3 and AGAINST proposal 4. This proxy, when properly executed, will be voted in the manner directed herein. If no direction is made, this proxy will be voted FOR all nominees for director, FOR proposals 2 and 3 and AGAINST proposal 4. In their discretion, the Named Proxies are authorized to vote upon such other matters that may properly come before the Annual Meeting or any adjournment or postponement thereof. You are encouraged to specify your choice by marking the appropriate box (SEE REVERSE SIDE), but you need not mark any box if you wish to vote in accordance with the Board of Directors recommendation. The Named Proxies cannot vote your shares unless you sign and return this card. To attend the meeting and vote your shares in person, please mark this box. Please separate carefully at the perforation and return just this portion in the envelope provided.